ClinicalTrials.gg
CompletedNCT01572038PERUSEUpdated Sep 25, 2020Results posted

A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer

A Phase 3 interventional study of Docetaxel and Nab-paclitaxel in Breast Neoplasms, sponsored by Hoffmann-La Roche. Completed at 299 sites in 39 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-25.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,436
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies testing pertuzumab in Breast Neoplasms — 26 open to participants now, 45 under way, 7 of them phase 3. pertuzumab · Breast Neoplasms.

Enrollment
5th of 104
1,436 · median 100
Started
2012
with 2 others
Phase 3
23 of 104
2 open now
Registered
14th of 104
by date
Lead sponsor
20 of 104
Hoffmann-La Roche

Among the 104 studies testing pertuzumab in Breast Neoplasms, this one is the 5th largest by enrollment, is one of 3 that started in 2012, is one of 23 in phase 3, and was the 14th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

26 of the 104 studies testing pertuzumab in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 26 open studies →

About pertuzumab

pertuzumab: first FDA approval 2012 (PERJETA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing pertuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This multicenter, open-label, single-arm, Phase IIIb study will evaluate the safety and tolerability of pertuzumab in combination with trastuzumab (Herceptin) and a taxane (docetaxel, paclitaxel or nab-paclitaxel) in first-line treatment in participants with metastatic or locally recurrent HER2-positive breast cancer. Participants will receive pertuzumab intravenously (IV) and trastuzumab (Herceptin) IV plus a taxane in cycles of 3 weeks each until predefined study end, unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first.

03

Conditions studied

  • Breast Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of the breast with or locally recurrent disease not amenable to curative resection
  • -positive breast cancer
  • (ECOG) performance status 0, 1 or 2
  • of at least 50 percent (%)

Exclusion criteria

Exclusion Criteria:

  • Previous systemic non-hormonal anti-cancer therapy for or locally recurrent disease
  • Disease-free interval from completion of or neoadjuvant systemic non-hormonal treatment to recurrence less than or equal to (\</=) 6 months
  • Previous approved or investigative anti- agents in any breast cancer treatment setting, except for trastuzumab and/or lapatinib in the adjuvant or neoadjuvant setting
  • Disease progression while receiving trastuzumab and/or lapatinib in the adjuvant or neoadjuvant setting
  • History of persistent Grade 2 or higher (National Cancer Institute Common Toxicity Criteria [NCI-CTC], Version 4.0) hematological toxicity resulting from previous adjuvant or neoadjuvant therapy
  • Central nervous system (CNS) metastases
  • Current peripheral neuropathy of Grade 3 or greater (NCI-CTC, version 4.0)
  • History of other within the last 5 years prior to first study drug administration, except for carcinoma in situ of the cervix or basal cell carcinoma
  • Inadequate bone marrow, liver or renal function
  • Uncontrolled hypertension
  • , or (HIV) infection
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,436 participants (actual)

Study arms

  • Experimental
    Pertuzumab + Trastuzumab + Taxane

    Participants will receive pertuzumab and trastuzumab (Herceptin) IV plus a taxane in cycles of 3 weeks each until predefined study end, unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first. Taxane chemotherapy can be either docetaxel, paclitaxel or nab-paclitaxel as per investigator's choice.

    Drug: Docetaxel · Drug: Nab-paclitaxel · Drug: Paclitaxel · Drug: Pertuzumab · Drug: Trastuzumab

Interventions

  • Participants may receive 'docetaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.

  • Participants may receive 'nab-paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.

  • Participants may receive 'paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.

  • Participants will receive pertuzumab 840 milligrams (mg) IV on Day 1 or Day 2 of Cycle 1, followed by 420 mg IV on Day 1 or Day 2 of each subsequent 3-week cycle.

    Also known as: RO 43-68451

  • Participants will receive trastuzumab (Herceptin) 8 milligrams per kilogram (mg/kg) IV on Day 1 or Day 2 of Cycle 1, followed by 6 mg/kg IV on Day 1 or Day 2 of each subsequent 3-week cycle, administered in line with the respective product Information and/or recognized clinical practice guidelines.

    Also known as: Herceptin

06

What researchers measure

Primary outcomes

  1. Overview of the Number of Participants With at Least One Treatment-Emergent Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0)

    Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. TEAEs to monitor included anaphylaxis and hypersensitivity, cardiac dysfunction, diarrhoea Grade ≥3, pregnancy-related AEs, interstitial lung disease, infusion-/administration-related reactions, mucositis, (febrile) neutropenia, rash/skin reactions, and suspected transmission of infectious agent. TEAEs of special interest included LVEF decreased, liver enzymes increased, and suspected transmission of infectious agent by the study drug.

    Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  2. Number of Participants Who Died Over the Course of the Study by Reported Cause of Death (Adverse Events Leading to Death by System Organ Class and Preferred Term)

    All adverse events leading to death, regardless of whether they were classified as treatment emergent, are listed by system organ class (SOC) and preferred term (PT) according to the Medical Dictionary for Regulatory Activities, version 22.1 (MedDRA version 22.1); PTs that are part of a given SOC are listed in the rows directly below each SOC within the results table. Admin. = administration; Mediast. = mediastinal

    Time frame: The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  3. Number of Participants Who Died Within 6 Months of Starting Study Treatment by Reported Cause of Death (Adverse Events Leading to Death by System Organ Class and Preferred Term)

    All adverse events leading to death, regardless of whether they were classified as treatment emergent, are listed by system organ class (SOC) and preferred term (PT) according to the Medical Dictionary for Regulatory Activities, version 22.1 (MedDRA version 22.1); PTs that are part of a given SOC are listed in the rows directly below each SOC within the results table. Admin. = administration; Mediast. = mediastinal

    Time frame: The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  4. Number of Participants With Grade ≥3 Treatment-Emergent Adverse Events, Occurring in ≥1% of Participants by System Organ Class and Preferred Term

    Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. MedDRA version 22.1 was used to code AEs by system organ class (SOC) and preferred term (PT); PTs that are part of a given SOC are listed in the rows directly below each SOC within the results table. If a participant experienced the same AE at more than one severity grade, only the most severe grade was presented.

    Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  5. Number of Participants With Treatment-Emergent Adverse Events of Any Grade That Were Related to Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ≥10% of Participants by System Organ Class

    Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. MedDRA version 22.1 was used to code AEs and the system organ classes are presented in descending order according to the total frequency of occurrence. If a participant experienced more than one event in a category, they were counted only once in that category.

    Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  6. Number of Participants With Grade ≥3 Treatment-Emergent Adverse Events That Were Related to Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ≥0.5% of Participants by Preferred Term

    Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. MedDRA version 22.1 was used to code AEs and the preferred terms are presented in descending order according to the total frequency of occurrence. If a participant experienced more than one event in a category, they were counted only once in that category.

    Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  7. Number of Participants With Treatment-Emergent Adverse Events Leading to Discontinuation of Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ≥0.2% of Participants by Preferred Term

    Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. MedDRA version 22.1 was used to code AEs and the preferred terms are presented in descending order according to the total frequency of occurrence. If a participant experienced more than one event in a category, they were counted only once in that category. Discont. = discontinuation; Ptz = pertuzumab; Tax = taxane; Trz = trastuzumab

    Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  8. Number of Participants With Treatment-Emergent Adverse Events Leading to Dose Interruption of Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ≥0.5% of Participants by Preferred Term

    Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. MedDRA version 22.1 was used to code AEs and the preferred terms are presented in descending order according to the total frequency of occurrence. If a participant experienced more than one event in a category, they were counted only once in that category. Interrupt. = interruption; Ptz = pertuzumab; Tax = taxane; Trz = trastuzumab

    Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  9. Number of Participants With Treatment-Emergent Adverse Events to Monitor of Any Grade, Occurring in ≥5% of Participants by Category

    Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first dose of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, it was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. If a participant had more than one event in a category, they were counted only once in that category. TEAEs to monitor included anaphylaxis and hypersensitivity, cardiac dysfunction, diarrhoea Grade ≥3, pregnancy-related AEs, interstitial lung disease, infusion-/administration-related reactions, mucositis, (febrile) neutropenia, rash/skin reactions, and suspected transmission of infectious agent. MedDRA version 22.1 was used to code AEs; AEs may fall within multiple categories.

    Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  10. Number of Participants With Grade ≥3 Treatment-Emergent Adverse Events to Monitor, Occurring in ≥0.5% of Participants by Category and Preferred Term

    Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first dose of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, it was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. If a participant had more than one event in a category, they were counted only once in that category. TEAEs to monitor included anaphylaxis and hypersensitivity, cardiac dysfunction, diarrhoea Grade ≥3, pregnancy-related AEs, interstitial lung disease, infusion-/administration-related reactions, mucositis, (febrile) neutropenia, rash/skin reactions, and suspected transmission of infectious agent. MedDRA version 22.1 was used to code AEs; preferred terms (PT) that are part of a given category are listed in the rows directly below each category within the results table.

    Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  11. Number of Participants With Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term

    Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. TEAEs of special interest included LVEF decreased, liver enzymes (ALT or AST) increased, and suspected transmission of infectious agent by the study drug. MedDRA version 22.1 was used to code AEs; preferred terms (PT) that are part of a given category are listed in the rows directly below each category within the results table. If a participant experienced more than one event in a category, they were counted only once in that category.

    Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  12. Subgroup Analysis by Region of Enrollment: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab

    Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.

    Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  13. Subgroup Analysis by Age (≤65 vs. >65 Years): Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), TEAEs Leading to Death, Grade ≥3 TEAEs, Any-Grade and Grade ≥3 TEAEs Related to Pertuzumab, and TEAEs to Monitor

    Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. TEAEs to monitor included anaphylaxis and hypersensitivity, cardiac dysfunction, diarrhoea Grade ≥3, pregnancy-related AEs, interstitial lung disease, infusion-/administration-related reactions, mucositis, (febrile) neutropenia, rash/skin reactions, and suspected transmission of infectious agent.

    Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  14. Subgroup Analysis by Taxane Chemotherapy: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), TEAEs Leading to Death, Grade ≥3 TEAEs, Any-Grade and Grade ≥3 TEAEs Related to Pertuzumab, and TEAEs to Monitor

    Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. TEAEs to monitor included anaphylaxis and hypersensitivity, cardiac dysfunction, diarrhoea Grade ≥3, pregnancy-related AEs, interstitial lung disease, infusion-/administration-related reactions, mucositis, (febrile) neutropenia, rash/skin reactions, and suspected transmission of infectious agent.

    Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  15. Subgroup Analysis by ECOG Performance Status at Baseline: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab

    Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.

    Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  16. Subgroup Analysis by Visceral Disease at Baseline: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab

    Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.

    Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  17. Subgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab

    Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.

    Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  18. Subgroup Analysis by Hormone Receptor Status at Baseline: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab

    Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.

    Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  19. Subgroup Analysis by Previous Trastuzumab Therapy: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab

    Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.

    Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  20. Number of Participants With a Congestive Heart Failure Event

    Congestive heart failure was defined as the Standardised MedDRA Query (SMQ) 'Cardiac failure (wide)' from the Medical Dictionary for Regulatory Activities, version 22.1 (MedDRA version 22.1).

    Time frame: From Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  21. Time to Onset of the First Episode of Congestive Heart Failure

    Congestive heart failure was defined as SMQ 'Cardiac failure (wide)' from the MedDRA version 22.1. Time to onset of the first episode of congestive heart failure was analyzed using a Kaplan-Meier approach. Participants who did not experience any congestive heart failure at the time of data-cut were censored at the date of the last attended visit whilst on-treatment (including visits up to and including 28 days after last dose of study treatment). Only treatment emergent congestive heart failure events are included.

    Time frame: From Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  22. Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Values Over the Course of the Study

    All participants must have had a baseline LVEF ≥50% to enroll in the study; patients with significant cardiac disease or baseline LVEF below 50% were not eligible for this study. The change from baseline LVEF values were reported at every 3 cycles over the course of the study and at the final treatment, worst treatment, and maximum decrease values. The final treatment value was defined as the last LVEF value observed before all study treatment discontinuation. The worst treatment value was defined as the lowest LVEF value observed before all study treatment discontinuation. The maximum decrease value was defined as the largest decrease of LVEF value from baseline, or minimum increase if a participant's post-baseline LVEF measures were all larger than the baseline value.

    Time frame: Baseline, predose on Day 1 of every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  23. Number of Participants by Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Categories Over the Course of the Study

    All participants must have had a baseline LVEF greater than or equal to (≥)50% to enroll in the study; patients with significant cardiac disease or baseline LVEF below 50% were not eligible for this study. The number of participants are reported according to four change from baseline in LVEF value categories over the course of the study: 1) an increase or decrease from baseline LVEF less than (\<)10% points or no change in LVEF; 2) an absolute LVEF value \<45% points and a decrease from baseline LVEF ≥10% points to \<15% points; 3) an absolute LVEF value \<45% points and a decrease from baseline LVEF ≥15% points; or 4) an absolute LVEF value ≥45% points and a decrease from baseline LVEF ≥10% points. BL = baseline; Decr. = decrease; Incr. = increase

    Time frame: Baseline, predose on Day 1 of every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  24. Number of Participants With Laboratory Abnormalities in Hematology and Coagulation Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to NCI-CTC v4.0

    Clinical laboratory tests for hematology and coagulation parameters were performed at local laboratories. Laboratory toxicities were defined based on NCI-CTC v4.0 from Grades 1 (least severe) to 4 (most severe). Some laboratory parameters are bi-dimensional (i.e. can be graded in both the low and high direction). These parameters were split and presented in both directions. Baseline was defined as the last non-missing measurement taken prior to the first dose of study treatment (including unscheduled assessments). Values from all visits, including unscheduled visits, were included in the derivation of the worst post-baseline grade. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: was clinically significant (per investigator); was accompanied by clinical symptoms; resulted in a change in study treatment; or resulted in a medical intervention or a change in concomitant therapy.

    Time frame: Predose at each treatment cycle (1 cycle is 3 weeks) from Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  25. Number of Participants With Laboratory Abnormalities in Hematology and Coagulation Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to Normal Range Criteria

    Clinical laboratory tests for hematology and coagulation parameters were performed at local laboratories. Laboratory toxicities were defined based on local laboratory normal ranges (for parameters with NCI-CTC grade not defined). Some laboratory parameters are bi-dimensional (i.e. can be graded in both the low and high direction). These parameters were split and presented in both directions. Baseline was defined as the last non-missing measurement taken prior to the first dose of study treatment (including unscheduled assessments). Values from all visits, including unscheduled visits, were included in the derivation of the worst post-baseline grade. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: was clinically significant (per investigator); was accompanied by clinical symptoms; resulted in a change in study treatment; or resulted in a medical intervention or a change in concomitant therapy.

    Time frame: Predose at each treatment cycle (1 cycle is 3 weeks) from Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  26. Number of Participants With Laboratory Abnormalities in Biochemistry Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to NCI-CTC v4.0

    Clinical laboratory tests for biochemistry parameters were performed at local laboratories. Laboratory toxicities were defined based on NCI-CTC v4.0 from Grades 1 (least severe) to 4 (most severe). Some laboratory parameters are bi-dimensional (i.e. can be graded in both the low and high direction). These parameters were split and presented in both directions. Baseline was defined as the last non-missing measurement taken prior to the first dose of study treatment (including unscheduled assessments). Values from all visits, including unscheduled visits, were included in the derivation of the worst post-baseline grade. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: was clinically significant (per investigator); was accompanied by clinical symptoms; resulted in a change in study treatment; or resulted in a medical intervention or a change in concomitant therapy.

    Time frame: Predose at each treatment cycle (1 cycle is 3 weeks) from Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  27. Number of Participants With Laboratory Abnormalities in Biochemistry Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to Normal Range Criteria

    Clinical laboratory tests for biochemistry parameters were performed at local laboratories. Laboratory toxicities were defined based on local laboratory normal ranges (for parameters with NCI-CTC grade not defined). Some laboratory parameters are bi-dimensional (i.e. can be graded in both the low and high direction). These parameters were split and presented in both directions. Baseline was defined as the last non-missing measurement taken prior to the first dose of study treatment (including unscheduled assessments). Values from all visits, including unscheduled visits, were included in the derivation of the worst post-baseline grade. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: was clinically significant (per investigator); was accompanied by clinical symptoms; resulted in a change in study treatment; or resulted in a medical intervention or a change in concomitant therapy.

    Time frame: Predose at each treatment cycle (1 cycle is 3 weeks) from Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

Secondary outcomes

  1. Progression-Free Survival, as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

    Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.

    Time frame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  2. Subgroup Analysis by Region of Enrollment: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1

    Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.

    Time frame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  3. Subgroup Analysis by Age (≤65 vs. >65 Years): Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1

    Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.

    Time frame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  4. Subgroup Analysis by ECOG Performance Status at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1

    Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.

    Time frame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  5. Subgroup Analysis by Taxane Chemotherapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1

    Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.

    Time frame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  6. Subgroup Analysis by Visceral Disease at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1

    Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.

    Time frame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  7. Subgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1

    Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.

    Time frame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  8. Subgroup Analysis by Hormone Receptor Status at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1

    Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.

    Time frame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  9. Subgroup Analysis by Previous Trastuzumab Therapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1

    Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.

    Time frame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  10. Overall Survival

    Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.

    Time frame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  11. Subgroup Analysis by Region of Enrollment: Overall Survival

    Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.

    Time frame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  12. Subgroup Analysis by Age (≤65 vs. >65 Years): Overall Survival

    Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.

    Time frame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  13. Subgroup Analysis by ECOG Performance Status at Baseline: Overall Survival

    Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.

    Time frame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  14. Subgroup Analysis by Taxane Chemotherapy: Overall Survival

    Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.

    Time frame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  15. Subgroup Analysis by Visceral Disease at Baseline: Overall Survival

    Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.

    Time frame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  16. Subgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Overall Survival

    Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.

    Time frame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  17. Subgroup Analysis by Hormone Receptor Status at Baseline: Overall Survival

    Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.

    Time frame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  18. Subgroup Analysis by Previous Trastuzumab Therapy: Overall Survival

    Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.

    Time frame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  19. Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.1

    The overall response rate was defined as the percentage of participants with complete response (CR) or partial response (PR) as their best confirmed response (≥4 weeks later), as assessed by the investigator using RECIST v1.1 from the start of study treatment until disease progression/recurrence or death. Responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants without post-baseline tumor assessments were considered non-responders.

    Time frame: Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression or death. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  20. Percentage of Participants by Best Overall Response as Assessed by the Investigator Using RECIST v1.1

    Best overall response (BOR) was defined as the best response recorded from the first dose of study treatment until disease progression/recurrence or death in the absence of disease progression. The hierarchy used to determine BOR: Complete Response (CR)\>Partial Response (PR)\>Stable Disease (SD)\>Progressive Disease (PD)\>Not Evaluable. Note that CR or PR was confirmed ≥4 weeks later. RECIST v1.1 responses are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum.; PD = At least 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study, and absolute increase of ≥5 mm.; SD = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression or death. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  21. Subgroup Analysis by Age (≤65 vs. >65 Years): Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.1

    The overall response rate was defined as the percentage of participants with complete response (CR) or partial response (PR) as their best confirmed response (≥4 weeks later), as assessed by the investigator using RECIST v1.1 from the start of study treatment until disease progression/recurrence or death. Responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants without post-baseline tumor assessments were considered non-responders.

    Time frame: Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression or death. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  22. Subgroup Analysis by Taxane Chemotherapy: Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.1

    The overall response rate was defined as the percentage of participants with complete response (CR) or partial response (PR) as their best confirmed response (≥4 weeks later), as assessed by the investigator using RECIST v1.1 from the start of study treatment until disease progression/recurrence or death. Responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants without post-baseline tumor assessments were considered non-responders.

    Time frame: Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression or death. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  23. Clinical Benefit Rate (CR or PR, or SD for at Least 6 Months) Based on Best Overall Response as Assessed by the Investigator Using RECIST v.1.1

    The clinical benefit rate was defined as the percentage of participants whose best confirmed response (≥4 weeks later) was a complete response (CR) or partial response (PR), or stable disease (SD) that lasted at least 6 months, as assessed by the investigator using RECIST v1.1 from the start of study treatment until disease progression/recurrence or death. Clinical benefit responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.; SD = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least 20% increase in sum of diameters of target lesions and absolute increase of ≥5 mm), taking as reference the smallest sum diameters while on study.

    Time frame: Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  24. Duration of Response as Assessed by the Investigator Using RECIST v1.1

    Duration of response (DOR) was defined as the time from when a confirmed best overall response of complete response (CR) or partial response (PR) was first documented to first documented disease progression or death from any cause (whichever occurred first). DOR was analyzed using a Kaplan-Meier approach. Participants who had not progressed or died after having had a confirmed response were censored at the date of their last tumor measurement. Response was assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter until event occurrence or end of study. Responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From date of first confirmed response (CR or PR) to first documented disease progression or death from any cause, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  25. Time to Response for Participants With Best Overall Response of Complete Response or Partial Response, as Assessed by the Investigator Using RECIST v1.1

    Time to response (TTR) was defined as the time from the first study treatment administration to the date of first confirmed response (CR or PR). TTR was analyzed using a Kaplan-Meier approach. Participants who did not have CR or PR were censored at the date of their last evaluable tumor assessment. Participants for whom no post-baseline tumor assessments were available were censored at Day 1. Responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From date of first study treatment until date of first confirmed response (CR or PR). The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.

  26. Change From Baseline in Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B) Questionnaire Total Score Over the Course of the Study

    The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. Participants were given a series of statements in each subscale and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B total score, ranging from 0 to 148, was the sum of the scores for each subscale, provided that at least 80% of the items had been answered; a higher score indicated a better quality of life. If any of the 5 subscale scores were missing, the total score was also set to missing. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.

    Time frame: Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  27. Change From Baseline in FACT-B Questionnaire Physical Well-Being Subscale Score Over the Course of the Study

    The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. For the physical well-being subscale, participants were given a series of 7 statements and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B physical well-being subscale score, ranging from 0 to 28, was the sum of the scores for each statement only if at least 50% of items had been answered; the higher the score, the better the quality of life. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.

    Time frame: Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  28. Change From Baseline in FACT-B Questionnaire Social Well-Being Subscale Score Over the Course of the Study

    The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. For the social well-being subscale, participants were given a series of 7 statements and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B social well-being subscale score, ranging from 0 to 28, was the sum of the scores for each statement only if at least 50% of items had been answered; the higher the score, the better the quality of life. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.

    Time frame: Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  29. Change From Baseline in FACT-B Questionnaire Emotional Well-Being Subscale Score Over the Course of the Study

    The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. For the emotional well-being subscale, participants were given a series of 6 statements and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B emotional well-being subscale score, ranging from 0 to 24, was the sum of the scores for each statement only if at least 50% of items had been answered; the higher the score, the better the quality of life. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.

    Time frame: Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  30. Change From Baseline in FACT-B Questionnaire Functional Well-Being Subscale Score Over the Course of the Study

    The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. For the functional well-being subscale, participants were given a series of 7 statements and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B functional well-being subscale score, ranging from 0 to 28, was the sum of the scores for each statement only if at least 50% of items had been answered; the higher the score, the better the quality of life. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.

    Time frame: Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

  31. Change From Baseline in FACT-B Questionnaire Breast Cancer Subscale Score Over the Course of the Study

    The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. For the breast cancer subscale, participants were given a series of 10 statements and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B breast cancer subscale score, ranging from 0 to 40, was the sum of the scores for each statement only if at least 50% of items had been answered; the higher the score, the better the quality of life. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.

    Time frame: Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.

07

Results

Posted Sep 25, 2020

Participant flow

Participant flow — Overall Study
MilestonePertuzumab + Trastuzumab + Taxane
Started1436
Received at least one dose of study drug1436
Completed445
Not completed991
Withdrew: Death648
Withdrew: Withdrawal by subject204
Withdrew: Lost to follow-up81
Withdrew: Physician decision20
Withdrew: Patient decision14
Withdrew: Progressive disease8
Withdrew: Site closed before completing form6
Withdrew: Enrolled into another trial3
Withdrew: Participated in another trial3
Withdrew: Termination by sponsor2
Withdrew: Patient deterioration1
Withdrew: Sponsor decision1

Outcome measures

PrimaryOverview of the Number of Participants With at Least One Treatment-Emergent Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0)

Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. TEAEs to monitor included anaphylaxis and hypersensitivity, cardiac dysfunction, diarrhoea Grade ≥3, pregnancy-related AEs, interstitial lung disease, infusion-/administration-related reactions, mucositis, (febrile) neutropenia, rash/skin reactions, and suspected transmission of infectious agent. TEAEs of special interest included LVEF decreased, liver enzymes increased, and suspected transmission of infectious agent by the study drug.

Time frame:
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Overview of the Number of Participants With at Least One Treatment-Emergent Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0)
ParticipantsPertuzumab + Trastuzumab + Taxane
Any TEAE - Any Grade1419
Any TEAE - Grade 3 or Higher (≥3)879
Any Serious TEAE535
Any TEAE Leading to Death31
Any TEAE Related to Pertuzumab - Any Grade1037
Any TEAE Related to Trastuzumab - Any Grade946
Any TEAE Related to Taxane - Any Grade1342
Any TEAE Related to Pertuzumab - Grade ≥3286
Any TEAE Related to Trastuzumab - Grade ≥3245
Any TEAE Related to Taxane - Grade ≥3514
Any TEAE Leading to Interruption of Pertuzumab334
Any TEAE Leading to Interruption of Trastuzumab386
Any TEAE Leading to Interruption of Taxane354
Any TEAE Leading to Discontinuation of Pertuzumab140
Any TEAE Leading to Discontinuation of Trastuzumab133
Any TEAE Leading to Discontinuation of Taxane286
Any TEAE to Monitor - Any Grade1320
Any TEAE to Monitor - Grade ≥3535
Any TEAE of Special Interest91
Any TEAE Within 28 Days of Treatmt Discontinuation975
PrimaryNumber of Participants Who Died Over the Course of the Study by Reported Cause of Death (Adverse Events Leading to Death by System Organ Class and Preferred Term)

All adverse events leading to death, regardless of whether they were classified as treatment emergent, are listed by system organ class (SOC) and preferred term (PT) according to the Medical Dictionary for Regulatory Activities, version 22.1 (MedDRA version 22.1); PTs that are part of a given SOC are listed in the rows directly below each SOC within the results table. Admin. = administration; Mediast. = mediastinal

Time frame:
The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Count of participants · Participants
Number of Participants Who Died Over the Course of the Study by Reported Cause of Death (Adverse Events Leading to Death by System Organ Class and Preferred Term)
ParticipantsPertuzumab + Trastuzumab + Taxane
Total Number of Deaths658
Number of Deaths by Cause: Progressive Disease581
Number of Deaths by Cause: Other42
Number of Deaths by Cause: Adverse Event (Total)35
Infections and Infestations (SOC)11
Peritonitis (PT)1
Pneumonia (PT)5
Respiratory Tract Infection (PT)1
Sepsis (PT)3
Septic Shock (PT)1
Cardiac Disorders (SOC)7
Cardiac Arrest (PT)2
Cardiac Failure (PT)1
Cardiac Failure Congestive (PT)1
Cardio-respiratory Arrest (PT)1
Myocardial Infarction (PT)1
Right Ventricular Failure (PT)1
General Disorders & Admin. Site Conditions (SOC)6
Death (PT)6
Blood and Lymphatic System Disorders (SOC)3
Febrile Neutropenia (PT)1
Neutropenia (PT)1
Thrombocytopenia (PT)1
Respiratory, Thoracic & Mediast. Disorders (SOC)3
Acute Respiratory Distress Syndrome (PT)1
Aspiration (PT)1
Pneumonitis (PT)1
Gastrointestinal Disorders (SOC)2
Pancreatitis (PT)1
Pancreatitis Chronic (PT)1
Nervous System Disorders (SOC)2
Hepatic Encephalopathy (PT)1
Ischemic Stroke (PT)1
Metabolism and Nutrition Disorders (SOC)1
Hypoglycaemia (PT)1
Hepatobiliary Disorders (SOC)1
Hepatic Failure (PT)1
Psychiatric Disorders (SOC)1
Delirium (PT)1
PrimaryNumber of Participants Who Died Within 6 Months of Starting Study Treatment by Reported Cause of Death (Adverse Events Leading to Death by System Organ Class and Preferred Term)

All adverse events leading to death, regardless of whether they were classified as treatment emergent, are listed by system organ class (SOC) and preferred term (PT) according to the Medical Dictionary for Regulatory Activities, version 22.1 (MedDRA version 22.1); PTs that are part of a given SOC are listed in the rows directly below each SOC within the results table. Admin. = administration; Mediast. = mediastinal

Time frame:
The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Count of participants · Participants
Number of Participants Who Died Within 6 Months of Starting Study Treatment by Reported Cause of Death (Adverse Events Leading to Death by System Organ Class and Preferred Term)
ParticipantsPertuzumab + Trastuzumab + Taxane
Total Number of Deaths38
Number of Deaths by Cause: Progressive Disease18
Number of Deaths by Cause: Other1
Number of Deaths by Cause: Adverse Event (Total)19
Infections and Infestations (SOC)6
Peritonitis (PT)1
Pneumonia (PT)2
Respiratory Tract Infection (PT)1
Sepsis (PT)2
General Disorders & Admin. Site Conditions (SOC)4
Death (PT)4
Blood and Lymphatic System Disorders (SOC)3
Febrile Neutropenia (PT)1
Neutropenia (PT)1
Thrombocytopenia (PT)1
Cardiac Disorders (SOC)2
Cardiac Arrest (PT)1
Cardio-Respiratory Arrest (PT)1
Respiratory, Thoracic & Mediast. Disorders (SOC)2
Acute Respiratory Distress Syndrome (PT)1
Pneumonitis (PT)1
Gastrointestinal Disorders (SOC)1
Pancreatitis (PT)1
Nervous System Disorders (SOC)1
Hepatic Encephalopathy (PT)1
Metabolism and Nutrition Disorders (SOC)1
Hypoglycaemia (PT)1
Hepatobiliary Disorders (SOC)1
Hepatic Failure (PT)1
PrimaryNumber of Participants With Grade ≥3 Treatment-Emergent Adverse Events, Occurring in ≥1% of Participants by System Organ Class and Preferred Term

Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. MedDRA version 22.1 was used to code AEs by system organ class (SOC) and preferred term (PT); PTs that are part of a given SOC are listed in the rows directly below each SOC within the results table. If a participant experienced the same AE at more than one severity grade, only the most severe grade was presented.

Time frame:
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Number of Participants With Grade ≥3 Treatment-Emergent Adverse Events, Occurring in ≥1% of Participants by System Organ Class and Preferred Term
ParticipantsPertuzumab + Trastuzumab + Taxane
Any TEAE - Grade (Gr.) 3676
Any TEAE - Gr. 4172
Any TEAE - Gr. 531
Gastrointestinal Disorders (SOC) - Gr. 3163
Gastrointestinal Disorders (SOC) - Gr. 44
Gastrointestinal Disorders (SOC) - Gr. 52
Diarrhoea (PT) - Gr. 3119
Diarrhoea (PT) - Gr. 41
Diarrhoea (PT) - Gr. 50
Vomiting (PT) - Gr. 319
Vomiting (PT) - Gr. 40
Vomiting (PT) - Gr. 50
Skin & Subcutaneous Tissue Disorders (SOC) - Gr. 356
Skin & Subcutaneous Tissue Disorders (SOC) - Gr. 40
Skin & Subcutaneous Tissue Disorders (SOC) - Gr. 50
Gen. Disorders & Admin.Site Conditions (SOC)-Gr. 3100
Gen. Disorders & Admin.Site Conditions (SOC)-Gr. 40
Gen. Disorders & Admin.Site Conditions (SOC)-Gr. 53
Fatigue (PT) - Gr. 336
Fatigue (PT) - Gr. 40
Fatigue (PT) - Gr. 50
Asthenia (PT) - Gr. 329
Asthenia (PT) - Gr. 40
Asthenia (PT) - Gr. 50
Mucosal Inflammation (PT) - Gr. 314
Mucosal Inflammation (PT) - Gr. 40
Mucosal Inflammation (PT) - Gr. 50
Nervous System Disorders (SOC) - Gr. 3139
Nervous System Disorders (SOC) - Gr. 40
Nervous System Disorders (SOC) - Gr. 52
Neuropathy Peripheral (PT) - Gr. 326
Neuropathy Peripheral (PT) - Gr. 40
Neuropathy Peripheral (PT) - Gr. 50
Syncope (PT) - Gr. 324
Syncope (PT) - Gr. 40
Syncope (PT) - Gr. 50
Headache (PT) - Gr. 317
Headache (PT) - Gr. 40
Headache (PT) - Gr. 50
Paraesthesia (PT) - Gr. 314
Paraesthesia (PT) - Gr. 40
Paraesthesia (PT) - Gr. 50
Peripheral Sensory Neuropathy (PT) - Gr. 314
Peripheral Sensory Neuropathy (PT) - Gr. 40
Peripheral Sensory Neuropathy (PT) - Gr. 50
Infections and Infestations (SOC) - Gr. 3148
Infections and Infestations (SOC) - Gr. 419
Infections and Infestations (SOC) - Gr. 510
Pneumonia (PT) - Gr. 322
Pneumonia (PT) - Gr. 41
Pneumonia (PT) - Gr. 54
Vascular Device Infection (PT) - Gr. 314
Vascular Device Infection (PT) - Gr. 40
Vascular Device Infection (PT) - Gr. 50
Device Related Infection (PT) - Gr. 314
Device Related Infection (PT) - Gr. 40
Device Related Infection (PT) - Gr. 50
Musculo. & Connective Tissue Disorders (SOC)-Gr. 375
Musculo. & Connective Tissue Disorders (SOC)-Gr. 40
Musculo. & Connective Tissue Disorders (SOC)-Gr. 50
Resp., Thoracic & Mediast. Disorders (SOC) - Gr. 362
Resp., Thoracic & Mediast. Disorders (SOC) - Gr. 45
Resp., Thoracic & Mediast. Disorders (SOC) - Gr. 53
Pulmonary Embolism (PT) - Gr. 321
Pulmonary Embolism (PT) - Gr. 42
Pulmonary Embolism (PT) - Gr. 50
Dyspnoea (PT) - Gr. 319
Dyspnoea (PT) - Gr. 41
Dyspnoea (PT) - Gr. 50
Blood & Lymphatic System Disorders (SOC) - Gr. 3158
Blood & Lymphatic System Disorders (SOC) - Gr. 4104
Blood & Lymphatic System Disorders (SOC) - Gr. 53
Neutropenia (PT) - Gr. 377
Neutropenia (PT) - Gr. 467
Neutropenia (PT) - Gr. 51
Febrile Neutropenia (PT) - Gr. 351
Febrile Neutropenia (PT) - Gr. 438
Febrile Neutropenia (PT) - Gr. 51
Anaemia (PT) - Gr. 329
Anaemia (PT) - Gr. 40
Anaemia (PT) - Gr. 50
Leukopenia (PT) - Gr. 315
Leukopenia (PT) - Gr. 43
Leukopenia (PT) - Gr. 50
Investigations (SOC) - Gr. 3116
Investigations (SOC) - Gr. 420
Investigations (SOC) - Gr. 50
Neutrophil Count Decreased (PT) - Gr. 325
Neutrophil Count Decreased (PT) - Gr. 413
Neutrophil Count Decreased (PT) - Gr. 50
Ejection Fraction Decreased (PT) - Gr. 322
Ejection Fraction Decreased (PT) - Gr. 42
Ejection Fraction Decreased (PT) - Gr. 50
Gamma-Glutamyltransferase Increased (PT) - Gr. 319
Gamma-Glutamyltransferase Increased (PT) - Gr. 41
Gamma-Glutamyltransferase Increased (PT) - Gr. 50
White Blood Cell Count Decreased (PT) - Gr. 316
White Blood Cell Count Decreased (PT) - Gr. 42
White Blood Cell Count Decreased (PT) - Gr. 50
Alanine Aminotransferase Increased (PT) - Gr. 316
Alanine Aminotransferase Increased (PT) - Gr. 40
Alanine Aminotransferase Increased (PT) - Gr. 50
Metabolism and Nutrition Disorders (SOC) - Gr. 363
Metabolism and Nutrition Disorders (SOC) - Gr. 48
Metabolism and Nutrition Disorders (SOC) - Gr. 51
Hypokalaemia (PT) - Gr. 319
Hypokalaemia (PT) - Gr. 41
Hypokalaemia (PT) - Gr. 50
Vascular Disorders (SOC) - Gr. 362
Vascular Disorders (SOC) - Gr. 42
Vascular Disorders (SOC) - Gr. 50
Hypertension (PT) - Gr. 345
Hypertension (PT) - Gr. 41
Hypertension (PT) - Gr. 50
Psychiatric Disorders (SOC) - Gr. 315
Psychiatric Disorders (SOC) - Gr. 43
Psychiatric Disorders (SOC) - Gr. 51
Injury, Poisoning & Proced. Complicat. (SOC)-Gr. 343
Injury, Poisoning & Proced. Complicat. (SOC)-Gr. 46
Injury, Poisoning & Proced. Complicat. (SOC)-Gr. 50
Cardiac Disorders (SOC) - Gr. 335
Cardiac Disorders (SOC) - Gr. 45
Cardiac Disorders (SOC) - Gr. 57
Immune System Disorders (SOC) - Gr. 317
Immune System Disorders (SOC) - Gr. 41
Immune System Disorders (SOC) - Gr. 50
Renal and Urinary Disorders (SOC) - Gr. 315
Renal and Urinary Disorders (SOC) - Gr. 43
Renal and Urinary Disorders (SOC) - Gr. 50
Neoplasms Benign, Malignant & Unspec. (SOC) -Gr. 313
Neoplasms Benign, Malignant & Unspec. (SOC) -Gr. 45
Neoplasms Benign, Malignant & Unspec. (SOC) -Gr. 50
Hepatobiliary Disorders (SOC) - Gr. 313
Hepatobiliary Disorders (SOC) - Gr. 40
Hepatobiliary Disorders (SOC) - Gr. 51
PrimaryNumber of Participants With Treatment-Emergent Adverse Events of Any Grade That Were Related to Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ≥10% of Participants by System Organ Class

Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. MedDRA version 22.1 was used to code AEs and the system organ classes are presented in descending order according to the total frequency of occurrence. If a participant experienced more than one event in a category, they were counted only once in that category.

Time frame:
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events of Any Grade That Were Related to Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ≥10% of Participants by System Organ Class
ParticipantsPertuzumab + Trastuzumab + Taxane
Any TEAE Related to Pertuzumab (Rel to Ptz)1037
Rel to Ptz: Gastrointestinal Disorders629
Rel to Ptz: Skin and Subcutaneous Tissue Disorders491
Rel to Ptz: Gen. Disorders & Admin.Site Conditions462
Rel to Ptz: Investigations252
Rel to Ptz: Nervous System Disorders207
Rel to Ptz: Resp., Thoracic & Mediast. Disorders188
Rel to Ptz: Musculo. & Connective Tissue Disorders184
Rel to Ptz: Blood & Lymphatic System Disorders182
Rel to Ptz: Infections and Infestations151
Any TEAE Related to Trastuzumab (Rel to Trz)946
Rel to Trz: Gastrointestinal Disorders435
Rel to Trz: Gen. Disorders & Admin.Site Conditions434
Rel to Trz: Skin and Subcutaneous Tissue Disorders384
Rel to Trz: Investigations262
Rel to Trz: Nervous System Disorders184
Rel to Trz: Musculo. & Connective Tissue Disorders179
Rel to Trz: Blood & Lymphatic System Disorders163
Rel to Trz: Resp., Thoracic & Mediast. Disorders153
Any TEAE Related to Taxane (Rel to Tax)1342
Rel to Tax: Gastrointestinal Disorders984
Rel to Tax: Skin and Subcutaneous Tissue Disorders938
Rel to Tax: Gen. Disorders & Admin.Site Conditions834
Rel to Tax: Nervous System Disorders764
Rel to Tax: Blood & Lymphatic System Disorders457
Rel to Tax: Musculo. & Connective Tissue Disorders386
Rel to Tax: Infections and Infestations293
Rel to Tax: Resp., Thoracic & Mediast. Disorders290
Rel to Tax: Metabolism and Nutrition Disorders227
Rel to Tax: Investigations201
Rel to Tax: Eye Disorders174
PrimaryNumber of Participants With Grade ≥3 Treatment-Emergent Adverse Events That Were Related to Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ≥0.5% of Participants by Preferred Term

Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. MedDRA version 22.1 was used to code AEs and the preferred terms are presented in descending order according to the total frequency of occurrence. If a participant experienced more than one event in a category, they were counted only once in that category.

Time frame:
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Number of Participants With Grade ≥3 Treatment-Emergent Adverse Events That Were Related to Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ≥0.5% of Participants by Preferred Term
ParticipantsPertuzumab + Trastuzumab + Taxane
Any Grade ≥3 TEAE Related to Pertuz. (Rel to Ptz)286
Rel to Ptz: Diarrhoea59
Rel to Ptz: Neutropenia28
Rel to Ptz: Febrile Neutropenia28
Rel to Ptz: Ejection Fraction Decreased19
Rel to Ptz: Neutrophil Count Decreased15
Rel to Ptz: Fatigue15
Rel to Ptz: Left Ventricular Dysfunction10
Rel to Ptz: Asthenia10
Rel to Ptz: White Blood Cell Count Decreased10
Rel to Ptz: Cardiac Failure9
Any Grade ≥3 TEAE Related to Trastuz. (Rel to Trz)245
Rel to Trz: Diarrhoea32
Rel to Trz: Neutropenia30
Rel to Trz: Ejection Fraction Decreased23
Rel to Trz: Febrile Neutropenia21
Rel to Trz: Neutrophil Count Decreased15
Rel to Trz: Fatigue14
Rel to Trz: Left Ventricular Dysfunction11
Rel to Trz: White Blood Cell Count Decreased10
Rel to Trz: Cardiac Failure8
Rel to Trz: Asthenia8
Any Grade ≥3 TEAE Related to Taxane (Rel to Tax)514
Rel to Tax: Neutropenia140
Rel to Tax: Febrile Neutropenia86
Rel to Tax: Diarrhoea80
Rel to Tax: Neutrophil Count Decreased34
Rel to Tax: Fatigue26
Rel to Tax: Peripheral Neuropathy24
Rel to Tax: Asthenia20
Rel to Tax: Leukopenia16
Rel to Tax: White Blood Cell Count Decreased16
Rel to Tax: Mucosal Inflammation14
Rel to Tax: Paraesthesia13
Rel to Tax: Peripheral Sensory Neuropathy13
Rel to Tax: Onycholysis10
Rel to Tax: Neutropenic Sepsis10
Rel to Tax: Anaemia10
Rel to Tax: Vomiting7
Rel to Tax: Neurotoxicity7
PrimaryNumber of Participants With Treatment-Emergent Adverse Events Leading to Discontinuation of Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ≥0.2% of Participants by Preferred Term

Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. MedDRA version 22.1 was used to code AEs and the preferred terms are presented in descending order according to the total frequency of occurrence. If a participant experienced more than one event in a category, they were counted only once in that category. Discont. = discontinuation; Ptz = pertuzumab; Tax = taxane; Trz = trastuzumab

Time frame:
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events Leading to Discontinuation of Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ≥0.2% of Participants by Preferred Term
ParticipantsPertuzumab + Trastuzumab + Taxane
Any TEAE, Pertuzumab Discontinuation (Ptz Discont)140
Ptz Discont: Ejection Fraction Decreased37
Ptz Discont: Cardiac Failure10
Ptz Discont: Left Ventricular Dysfunction7
Ptz Discont: Diarrhoea7
Ptz Discont: Dyspnoea4
Ptz Discont: Infusion Related Reaction4
Ptz Discont: Sepsis3
Ptz Discont: Neuropathy Peripheral3
Ptz Discont: Hypersensitivity3
Ptz Discont: General Physical Health Deterioration3
Any TEAE, Trastuzumab Discontinuation(Trz Discont)133
Trz Discont: Ejection Fraction Decreased37
Trz Discont: Cardiac Failure10
Trz Discont: Left Ventricular Dysfunction7
Trz Discont: Diarrhoea6
Trz Discont: Sepsis3
Trz Discont: Dyspnoea3
Trz Discont: Neuropathy Peripheral3
Trz Discont: Hypersensitivity3
Trz Discont: General Physical Health Deterioration3
Any TEAE, Taxane Discontinuation (Tax Discont)286
Tax Discont: Neuropathy Peripheral52
Tax Discont: Peripheral Sensory Neuropathy25
Tax Discont: Paraesthesia24
Tax Discont: Diarrhoea19
Tax Discont: Fatigue16
Tax Discont: Asthenia13
Tax Discont: Onycholysis8
Tax Discont: Nail Toxicity7
Tax Discont: Neurotoxicity7
Tax Discont: Polyneuropathy7
Tax Discont: Oedema Peripheral7
Tax Discont: Febrile Neutropenia7
Tax Discont: Neutropenia7
Tax Discont: Dyspnoea6
Tax Discont: Decreased Appetite6
Tax Discont: Ejection Fraction Decreased5
Tax Discont: General Physical Health Deterioration4
Tax Discont: Mucosal Inflammation4
Tax Discont: Rash4
Tax Discont: Anaemia4
Tax Discont: Arthralgia4
Tax Discont: Drug Hypersensitivity4
Tax Discont: Dysgeusia3
Tax Discont: Nail Disorder3
Tax Discont: Nail Dystrophy3
Tax Discont: Skin Toxicity3
Tax Discont: Pneumonia3
Tax Discont: Sepsis3
Tax Discont: Pleural Effusion3
Tax Discont: Pneumonitis3
Tax Discont: Cardiac Failure3
Tax Discont: Myalgia3
PrimaryNumber of Participants With Treatment-Emergent Adverse Events Leading to Dose Interruption of Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ≥0.5% of Participants by Preferred Term

Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. MedDRA version 22.1 was used to code AEs and the preferred terms are presented in descending order according to the total frequency of occurrence. If a participant experienced more than one event in a category, they were counted only once in that category. Interrupt. = interruption; Ptz = pertuzumab; Tax = taxane; Trz = trastuzumab

Time frame:
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events Leading to Dose Interruption of Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ≥0.5% of Participants by Preferred Term
ParticipantsPertuzumab + Trastuzumab + Taxane
Any TEAE, Pertuzumab Interruption (Ptz Interrupt)334
Ptz Interrupt: Ejection Fraction Decreased51
Ptz Interrupt: Diarrhoea21
Ptz Interrupt: Neutropenia17
Ptz Interrupt: Pneumonia14
Ptz Interrupt: Upper Respiratory Tract Infection13
Ptz Interrupt: Pyrexia11
Ptz Interrupt: Dyspnoea11
Ptz Interrupt: Drug Hypersensitivity9
Ptz Interrupt: Influenza8
Ptz Interrupt: Asthenia8
Ptz Interrupt: Neutrophil Count Decreased8
Ptz Interrupt: Nasopharyngitis7
Ptz Interrupt: Anaemia7
Any TEAE, Trastuzumab Interruption (Trz Interrupt)386
Trz Interrupt: Ejection Fraction Decreased52
Trz Interrupt: Drug Hypersensitivity31
Trz Interrupt: Diarrhoea20
Trz Interrupt: Pyrexia18
Trz Interrupt: Neutropenia17
Trz Interrupt: Dyspnoea17
Trz Interrupt: Pneumonia14
Trz Interrupt: Chills13
Trz Interrupt: Infusion Related Reaction13
Trz Interrupt: Upper Respiratory Tract Infection12
Trz Interrupt: Neutrophil Count Decreased8
Trz Interrupt: Influenza7
Trz Interrupt: Asthenia7
Trz Interrupt: Vomiting7
Trz Interrupt: Anaemia7
Trz Interrupt: Nasopharyngitis7
Any TEAE, Taxane Interruption (Tax Interrupt)354
Tax Interrupt: Neutropenia46
Tax Interrupt: Diarrhoea30
Tax Interrupt: Leukopenia17
Tax Interrupt: Dyspnoea15
Tax Interrupt: Pyrexia14
Tax Interrupt: Neutrophil Count Decreased14
Tax Interrupt: Ejection Fraction Decreased13
Tax Interrupt: Neuropathy Peripheral13
Tax Interrupt: Nasopharyngitis10
Tax Interrupt: Drug Hypersensitivity10
Tax Interrupt: Fatigue10
Tax Interrupt: Upper Respiratory Tract Infection9
Tax Interrupt: Infusion Related Reaction9
Tax Interrupt: Asthenia9
Tax Interrupt: Erythema8
Tax Interrupt: Pneumonia7
Tax Interrupt: Flushing7
Tax Interrupt: Hypersensitivity7
PrimaryNumber of Participants With Treatment-Emergent Adverse Events to Monitor of Any Grade, Occurring in ≥5% of Participants by Category

Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first dose of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, it was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. If a participant had more than one event in a category, they were counted only once in that category. TEAEs to monitor included anaphylaxis and hypersensitivity, cardiac dysfunction, diarrhoea Grade ≥3, pregnancy-related AEs, interstitial lung disease, infusion-/administration-related reactions, mucositis, (febrile) neutropenia, rash/skin reactions, and suspected transmission of infectious agent. MedDRA version 22.1 was used to code AEs; AEs may fall within multiple categories.

Time frame:
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events to Monitor of Any Grade, Occurring in ≥5% of Participants by Category
ParticipantsPertuzumab + Trastuzumab + Taxane
Any TEAE to Monitor1320
Infusion-/Administration-Related Reactions1096
Rash/Skin Reactions668
Mucositis618
Cardiac Dysfunction478
Neutropenia/Febrile Neutropenia439
Anaphylaxis and Hypersensitivity124
Diarrhoea Grade ≥3120
PrimaryNumber of Participants With Grade ≥3 Treatment-Emergent Adverse Events to Monitor, Occurring in ≥0.5% of Participants by Category and Preferred Term

Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first dose of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, it was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. If a participant had more than one event in a category, they were counted only once in that category. TEAEs to monitor included anaphylaxis and hypersensitivity, cardiac dysfunction, diarrhoea Grade ≥3, pregnancy-related AEs, interstitial lung disease, infusion-/administration-related reactions, mucositis, (febrile) neutropenia, rash/skin reactions, and suspected transmission of infectious agent. MedDRA version 22.1 was used to code AEs; preferred terms (PT) that are part of a given category are listed in the rows directly below each category within the results table.

Time frame:
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Number of Participants With Grade ≥3 Treatment-Emergent Adverse Events to Monitor, Occurring in ≥0.5% of Participants by Category and Preferred Term
ParticipantsPertuzumab + Trastuzumab + Taxane
Any Grade ≥3 TEAE to Monitor535
Neutropenia/Febrile Neutropenia (Category)279
Neutropenia (PT)145
Febrile Neutropenia (PT)90
Neutrophil Count Decreased (PT)38
Leukopenia (PT)18
White Blood Cell Count Decreased (PT)18
Neutropenic Sepsis (PT)10
Infusion-/Admin.-Related Reactions (Category)123
Hypertension (PT)27
IRR/ARR: Drug Hypersensitivity (PT)12
Asthenia (PT)11
Fatigue (PT)11
Dyspnoea (PT)10
Infusion Related Reaction (PT)8
Paraesthesia (PT)7
Diarrhoea Grade ≥3 (Category)120
Diarrhoea (PT)120
Cardiac Dysfunction (Category)51
Ejection Fraction Decreased (PT)24
Left Ventricular Dysfunction (PT)11
Cardiac Failure (PT)9
Mucositis (Category)33
Mucosal Inflammation (PT)14
Stomatitis (PT)9
Rash/Skin Reactions (Category)28
Rash (PT)10
Anaphylaxis and Hypersensitivity (Category)18
Anaphyl./Hypersens.: Drug Hypersensitivity (PT)13
PrimaryNumber of Participants With Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term

Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. TEAEs of special interest included LVEF decreased, liver enzymes (ALT or AST) increased, and suspected transmission of infectious agent by the study drug. MedDRA version 22.1 was used to code AEs; preferred terms (PT) that are part of a given category are listed in the rows directly below each category within the results table. If a participant experienced more than one event in a category, they were counted only once in that category.

Time frame:
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term
ParticipantsPertuzumab + Trastuzumab + Taxane
Any TEAE of Special Interest91
Decline in LVEF (Category)90
Ejection Fraction Decreased (PT)75
Left Ventricular Dysfunction (PT)8
Cardiac Failure (PT)7
Cardiac Failure Congestive (PT)1
Elevated ALT or AST (Category)1
Hepatic Failure (PT)1
PrimarySubgroup Analysis by Region of Enrollment: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab

Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.

Time frame:
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Subgroup Analysis by Region of Enrollment: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab
ParticipantsEuropeAsiaNorth AmericaSouth AmericaAfricaOther (Australia)
Any Serious TEAE385749371614
Any TEAE - Grade 3 or Higher (≥3)63210922633716
Any Grade ≥3 TEAE Related to Pertuzumab18744527194
PrimarySubgroup Analysis by Age (≤65 vs. >65 Years): Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), TEAEs Leading to Death, Grade ≥3 TEAEs, Any-Grade and Grade ≥3 TEAEs Related to Pertuzumab, and TEAEs to Monitor

Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. TEAEs to monitor included anaphylaxis and hypersensitivity, cardiac dysfunction, diarrhoea Grade ≥3, pregnancy-related AEs, interstitial lung disease, infusion-/administration-related reactions, mucositis, (febrile) neutropenia, rash/skin reactions, and suspected transmission of infectious agent.

Time frame:
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Subgroup Analysis by Age (≤65 vs. >65 Years): Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), TEAEs Leading to Death, Grade ≥3 TEAEs, Any-Grade and Grade ≥3 TEAEs Related to Pertuzumab, and TEAEs to Monitor
ParticipantsAge ≤65 YearsAge >65 Years
Any Serious TEAE415120
Any TEAE Leading to Death1714
Any TEAE - Grade 3 or Higher (≥3)688191
Any TEAE Related to Pertuzumab - Any Grade845192
Any Grade ≥3 TEAE Related to Pertuzumab22462
Any TEAE to Monitor - Any Grade1081239
PrimarySubgroup Analysis by Taxane Chemotherapy: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), TEAEs Leading to Death, Grade ≥3 TEAEs, Any-Grade and Grade ≥3 TEAEs Related to Pertuzumab, and TEAEs to Monitor

Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. TEAEs to monitor included anaphylaxis and hypersensitivity, cardiac dysfunction, diarrhoea Grade ≥3, pregnancy-related AEs, interstitial lung disease, infusion-/administration-related reactions, mucositis, (febrile) neutropenia, rash/skin reactions, and suspected transmission of infectious agent.

Time frame:
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Subgroup Analysis by Taxane Chemotherapy: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), TEAEs Leading to Death, Grade ≥3 TEAEs, Any-Grade and Grade ≥3 TEAEs Related to Pertuzumab, and TEAEs to Monitor
ParticipantsDocetaxelPaclitaxelNab-Paclitaxel
Any Serious TEAE30021022
Any TEAE Leading to Death14161
Any TEAE - Grade 3 or Higher (≥3)49134936
Any TEAE Related to Pertuzumab - Any Grade54743452
Any Grade ≥3 TEAE Related to Pertuzumab1711059
Any TEAE to Monitor - Any Grade70954164
PrimarySubgroup Analysis by ECOG Performance Status at Baseline: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab

Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.

Time frame:
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Subgroup Analysis by ECOG Performance Status at Baseline: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab
ParticipantsECOG Performance Status 0 or 1ECOG Performance Status 2
Any Serious TEAE50233
Any TEAE - Grade 3 or Higher (≥3)83741
Any Grade ≥3 TEAE Related to Pertuzumab27313
PrimarySubgroup Analysis by Visceral Disease at Baseline: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab

Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.

Time frame:
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Subgroup Analysis by Visceral Disease at Baseline: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab
ParticipantsVisceral DiseaseNon-Visceral Disease
Any Serious TEAE353182
Any TEAE - Grade 3 or Higher (≥3)610269
Any Grade ≥3 TEAE Related to Pertuzumab19789
PrimarySubgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab

Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.

Time frame:
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Subgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab
ParticipantsPrior (Neo)Adjuvant ChemotherapyNo Prior (Neo)Adjuvant Chemotherapy
Any Serious TEAE283252
Any TEAE - Grade 3 or Higher (≥3)493386
Any Grade ≥3 TEAE Related to Pertuzumab169117
PrimarySubgroup Analysis by Hormone Receptor Status at Baseline: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab

Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.

Time frame:
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Subgroup Analysis by Hormone Receptor Status at Baseline: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab
ParticipantsHormone Receptor PositiveHormone Receptor NegativeHormone Receptor Status Unknown
Any Serious TEAE3531793
Any TEAE - Grade 3 or Higher (≥3)5733033
Any Grade ≥3 TEAE Related to Pertuzumab1811032
PrimarySubgroup Analysis by Previous Trastuzumab Therapy: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab

Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.

Time frame:
From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Subgroup Analysis by Previous Trastuzumab Therapy: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab
ParticipantsPrevious Trastuzumab TherapyNo Previous Trastuzumab Therapy
Any Serious TEAE135400
Any TEAE - Grade 3 or Higher (≥3)238641
Any Grade ≥3 TEAE Related to Pertuzumab77209
PrimaryNumber of Participants With a Congestive Heart Failure Event

Congestive heart failure was defined as the Standardised MedDRA Query (SMQ) 'Cardiac failure (wide)' from the Medical Dictionary for Regulatory Activities, version 22.1 (MedDRA version 22.1).

Time frame:
From Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Number of Participants With a Congestive Heart Failure Event
ParticipantsPertuzumab + Trastuzumab + Taxane
Number of Participants With a Congestive Heart Failure Event478
PrimaryTime to Onset of the First Episode of Congestive Heart Failure

Congestive heart failure was defined as SMQ 'Cardiac failure (wide)' from the MedDRA version 22.1. Time to onset of the first episode of congestive heart failure was analyzed using a Kaplan-Meier approach. Participants who did not experience any congestive heart failure at the time of data-cut were censored at the date of the last attended visit whilst on-treatment (including visits up to and including 28 days after last dose of study treatment). Only treatment emergent congestive heart failure events are included.

Time frame:
From Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Median · Months
Time to Onset of the First Episode of Congestive Heart Failure
MonthsPertuzumab + Trastuzumab + Taxane
Time to Onset of the First Episode of Congestive Heart FailureNA (73.82 to NA)
PrimaryChange From Baseline in Left Ventricular Ejection Fraction (LVEF) Values Over the Course of the Study

All participants must have had a baseline LVEF ≥50% to enroll in the study; patients with significant cardiac disease or baseline LVEF below 50% were not eligible for this study. The change from baseline LVEF values were reported at every 3 cycles over the course of the study and at the final treatment, worst treatment, and maximum decrease values. The final treatment value was defined as the last LVEF value observed before all study treatment discontinuation. The worst treatment value was defined as the lowest LVEF value observed before all study treatment discontinuation. The maximum decrease value was defined as the largest decrease of LVEF value from baseline, or minimum increase if a participant's post-baseline LVEF measures were all larger than the baseline value.

Time frame:
Baseline, predose on Day 1 of every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Mean · Percentage points of LVEF
Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Values Over the Course of the Study
Percentage points of LVEFPertuzumab + Trastuzumab + Taxane
Baseline (BL): Absolute Value at Visit64.6 ± 6.46
Change from BL at Cycle 3-1.1 ± 6.49
Change from BL at Cycle 6-1.5 ± 6.60
Change from BL at Cycle 9-2.1 ± 6.56
Change from BL at Cycle 12-1.9 ± 6.66
Change from BL at Cycle 15-2.2 ± 6.50
Change from BL at Cycle 18-1.8 ± 6.77
Change from BL at Cycle 21-1.9 ± 6.79
Change from BL at Cycle 24-1.9 ± 6.93
Change from BL at Cycle 27-2.1 ± 6.81
Change from BL at Cycle 30-1.8 ± 6.80
Change from BL at Cycle 33-1.9 ± 6.97
Change from BL at Cycle 36-2.1 ± 6.53
Change from BL at Cycle 39-2.1 ± 6.77
Change from BL at Cycle 42-1.9 ± 6.52
Change from BL at Cycle 45-2.2 ± 6.94
Change from BL at Cycle 48-2.1 ± 6.67
Change from BL at Cycle 51-1.6 ± 6.75
Change from BL at Cycle 54-1.7 ± 6.38
Change from BL at Cycle 57-1.7 ± 6.87
Change from BL at Cycle 60-1.5 ± 6.46
Change from BL at Cycle 63-1.6 ± 7.13
Change from BL at Cycle 66-2.0 ± 6.63
Change from BL at Cycle 69-1.9 ± 6.45
Change from BL at Cycle 72-2.1 ± 6.80
Change from BL at Cycle 75-1.5 ± 6.84
Change from BL at Cycle 78-1.8 ± 7.41
Change from BL at Cycle 81-1.8 ± 6.98
Change from BL at Cycle 84-1.6 ± 6.89
Change from BL at Cycle 87-1.9 ± 6.31
Change from BL at Cycle 90-1.1 ± 6.68
Change from BL at Cycle 93-1.6 ± 6.78
Change from BL at Cycle 96-1.8 ± 6.33
Change from BL at Cycle 99-2.0 ± 7.20
Change from BL at Cycle 102-2.5 ± 7.95
Change from BL at Cycle 105-2.5 ± 6.86
Change from BL at Cycle 108-1.8 ± 8.04
Change from BL at Cycle 111-3.3 ± 7.47
Change from BL at Cycle 114-1.1 ± 8.12
Change from BL at Cycle 117-5.8 ± 7.48
Change from BL at Cycle 120-8.6 ± 6.70
Change from BL at Cycle 123-9.3 ± 3.51
Change from BL at Cycle 126-9.0 ± NA
Change from BL at End of Treatment-3.8 ± 8.34
Change from BL at Day 28 of Follow-Up-3.2 ± 8.19
Change from BL: Final Treatment Value-2.0 ± 6.77
Change from BL: Worst Treatment Value-7.1 ± 6.88
Change from BL: Maximum Decrease Value-7.7 ± 7.45
PrimaryNumber of Participants by Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Categories Over the Course of the Study

All participants must have had a baseline LVEF greater than or equal to (≥)50% to enroll in the study; patients with significant cardiac disease or baseline LVEF below 50% were not eligible for this study. The number of participants are reported according to four change from baseline in LVEF value categories over the course of the study: 1) an increase or decrease from baseline LVEF less than (\<)10% points or no change in LVEF; 2) an absolute LVEF value \<45% points and a decrease from baseline LVEF ≥10% points to \<15% points; 3) an absolute LVEF value \<45% points and a decrease from baseline LVEF ≥15% points; or 4) an absolute LVEF value ≥45% points and a decrease from baseline LVEF ≥10% points. BL = baseline; Decr. = decrease; Incr. = increase

Time frame:
Baseline, predose on Day 1 of every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Number of Participants by Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Categories Over the Course of the Study
ParticipantsPertuzumab + Trastuzumab + Taxane
Cycle 3 — Incr. or Decr. from BL <10% Points, or No Change1190
Cycle 3 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points2
Cycle 3 — LVEF<45% Points and Decr. from BL ≥15% Points5
Cycle 3 — LVEF≥45% Points and Decr. from BL ≥10% Points114
Cycle 6 — Incr. or Decr. from BL <10% Points, or No Change1110
Cycle 6 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 6 — LVEF<45% Points and Decr. from BL ≥15% Points2
Cycle 6 — LVEF≥45% Points and Decr. from BL ≥10% Points136
Cycle 9 — Incr. or Decr. from BL <10% Points, or No Change1005
Cycle 9 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points2
Cycle 9 — LVEF<45% Points and Decr. from BL ≥15% Points4
Cycle 9 — LVEF≥45% Points and Decr. from BL ≥10% Points139
Cycle 12 — Incr. or Decr. from BL <10% Points, or No Change906
Cycle 12 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 12 — LVEF<45% Points and Decr. from BL ≥15% Points6
Cycle 12 — LVEF≥45% Points and Decr. from BL ≥10% Points116
Cycle 15 — Incr. or Decr. from BL <10% Points, or No Change780
Cycle 15 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points3
Cycle 15 — LVEF<45% Points and Decr. from BL ≥15% Points6
Cycle 15 — LVEF≥45% Points and Decr. from BL ≥10% Points109
Cycle 18 — Incr. or Decr. from BL <10% Points, or No Change719
Cycle 18 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 18 — LVEF<45% Points and Decr. from BL ≥15% Points5
Cycle 18 — LVEF≥45% Points and Decr. from BL ≥10% Points92
Cycle 21 — Incr. or Decr. from BL <10% Points, or No Change639
Cycle 21 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 21 — LVEF<45% Points and Decr. from BL ≥15% Points4
Cycle 21 — LVEF≥45% Points and Decr. from BL ≥10% Points88
Cycle 24 — Incr. or Decr. from BL <10% Points, or No Change588
Cycle 24 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 24 — LVEF<45% Points and Decr. from BL ≥15% Points2
Cycle 24 — LVEF≥45% Points and Decr. from BL ≥10% Points91
Cycle 27 — Incr. or Decr. from BL <10% Points, or No Change553
Cycle 27 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 27 — LVEF<45% Points and Decr. from BL ≥15% Points2
Cycle 27 — LVEF≥45% Points and Decr. from BL ≥10% Points78
Cycle 30 — Incr. or Decr. from BL <10% Points, or No Change518
Cycle 30 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 30 — LVEF<45% Points and Decr. from BL ≥15% Points1
Cycle 30 — LVEF≥45% Points and Decr. from BL ≥10% Points70
Cycle 33 — Incr. or Decr. from BL <10% Points, or No Change485
Cycle 33 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 33 — LVEF<45% Points and Decr. from BL ≥15% Points1
Cycle 33 — LVEF≥45% Points and Decr. from BL ≥10% Points72
Cycle 36 — Incr. or Decr. from BL <10% Points, or No Change446
Cycle 36 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 36 — LVEF<45% Points and Decr. from BL ≥15% Points1
Cycle 36 — LVEF≥45% Points and Decr. from BL ≥10% Points62
Cycle 39 — Incr. or Decr. from BL <10% Points, or No Change414
Cycle 39 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points1
Cycle 39 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 39 — LVEF≥45% Points and Decr. from BL ≥10% Points65
Cycle 42 — Incr. or Decr. from BL <10% Points, or No Change405
Cycle 42 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 42 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 42 — LVEF≥45% Points and Decr. from BL ≥10% Points46
Cycle 45 — Incr. or Decr. from BL <10% Points, or No Change358
Cycle 45 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 45 — LVEF<45% Points and Decr. from BL ≥15% Points1
Cycle 45 — LVEF≥45% Points and Decr. from BL ≥10% Points69
Cycle 48 — Incr. or Decr. from BL <10% Points, or No Change340
Cycle 48 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 48 — LVEF<45% Points and Decr. from BL ≥15% Points1
Cycle 48 — LVEF≥45% Points and Decr. from BL ≥10% Points49
Cycle 51 — Incr. or Decr. from BL <10% Points, or No Change314
Cycle 51 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 51 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 51 — LVEF≥45% Points and Decr. from BL ≥10% Points43
Cycle 54 — Incr. or Decr. from BL <10% Points, or No Change292
Cycle 54 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 54 — LVEF<45% Points and Decr. from BL ≥15% Points3
Cycle 54 — LVEF≥45% Points and Decr. from BL ≥10% Points30
Cycle 57 — Incr. or Decr. from BL <10% Points, or No Change291
Cycle 57 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 57 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 57 — LVEF≥45% Points and Decr. from BL ≥10% Points41
Cycle 60 — Incr. or Decr. from BL <10% Points, or No Change284
Cycle 60 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 60 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 60 — LVEF≥45% Points and Decr. from BL ≥10% Points29
Cycle 63 — Incr. or Decr. from BL <10% Points, or No Change263
Cycle 63 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 63 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 63 — LVEF≥45% Points and Decr. from BL ≥10% Points39
Cycle 66 — Incr. or Decr. from BL <10% Points, or No Change249
Cycle 66 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 66 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 66 — LVEF≥45% Points and Decr. from BL ≥10% Points35
Cycle 69 — Incr. or Decr. from BL <10% Points, or No Change237
Cycle 69 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 69 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 69 — LVEF≥45% Points and Decr. from BL ≥10% Points33
Cycle 72 — Incr. or Decr. from BL <10% Points, or No Change224
Cycle 72 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 72 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 72 — LVEF≥45% Points and Decr. from BL ≥10% Points35
Cycle 75 — Incr. or Decr. from BL <10% Points, or No Change224
Cycle 75 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 75 — LVEF<45% Points and Decr. from BL ≥15% Points1
Cycle 75 — LVEF≥45% Points and Decr. from BL ≥10% Points29
Cycle 78 — Incr. or Decr. from BL <10% Points, or No Change214
Cycle 78 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 78 — LVEF<45% Points and Decr. from BL ≥15% Points2
Cycle 78 — LVEF≥45% Points and Decr. from BL ≥10% Points29
Cycle 81 — Incr. or Decr. from BL <10% Points, or No Change196
Cycle 81 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 81 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 81 — LVEF≥45% Points and Decr. from BL ≥10% Points30
Cycle 84 — Incr. or Decr. from BL <10% Points, or No Change192
Cycle 84 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 84 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 84 — LVEF≥45% Points and Decr. from BL ≥10% Points23
Cycle 87 — Incr. or Decr. from BL <10% Points, or No Change174
Cycle 87 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 87 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 87 — LVEF≥45% Points and Decr. from BL ≥10% Points22
Cycle 90 — Incr. or Decr. from BL <10% Points, or No Change161
Cycle 90 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 90 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 90 — LVEF≥45% Points and Decr. from BL ≥10% Points16
Cycle 93 — Incr. or Decr. from BL <10% Points, or No Change140
Cycle 93 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 93 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 93 — LVEF≥45% Points and Decr. from BL ≥10% Points16
Cycle 96 — Incr. or Decr. from BL <10% Points, or No Change115
Cycle 96 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 96 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 96 — LVEF≥45% Points and Decr. from BL ≥10% Points13
Cycle 99 — Incr. or Decr. from BL <10% Points, or No Change92
Cycle 99 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 99 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 99 — LVEF≥45% Points and Decr. from BL ≥10% Points14
Cycle 102 — Incr. or Decr. from BL <10% Points, or No Change68
Cycle 102 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 102 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 102 — LVEF≥45% Points and Decr. from BL ≥10% Points14
Cycle 105 — Incr. or Decr. from BL <10% Points, or No Change56
Cycle 105 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 105 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 105 — LVEF≥45% Points and Decr. from BL ≥10% Points9
Cycle 108 — Incr. or Decr. from BL <10% Points, or No Change41
Cycle 108 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 108 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 108 — LVEF≥45% Points and Decr. from BL ≥10% Points8
Cycle 111 — Incr. or Decr. from BL <10% Points, or No Change34
Cycle 111 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 111 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 111 — LVEF≥45% Points and Decr. from BL ≥10% Points8
Cycle 114 — Incr. or Decr. from BL <10% Points, or No Change19
Cycle 114 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 114 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 114 — LVEF≥45% Points and Decr. from BL ≥10% Points4
Cycle 117 — Incr. or Decr. from BL <10% Points, or No Change11
Cycle 117 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 117 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 117 — LVEF≥45% Points and Decr. from BL ≥10% Points6
Cycle 120 — Incr. or Decr. from BL <10% Points, or No Change4
Cycle 120 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 120 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 120 — LVEF≥45% Points and Decr. from BL ≥10% Points3
Cycle 123 — Incr. or Decr. from BL <10% Points, or No Change2
Cycle 123 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 123 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 123 — LVEF≥45% Points and Decr. from BL ≥10% Points1
Cycle 126 — Incr. or Decr. from BL <10% Points, or No Change1
Cycle 126 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points0
Cycle 126 — LVEF<45% Points and Decr. from BL ≥15% Points0
Cycle 126 — LVEF≥45% Points and Decr. from BL ≥10% Points0
End of Treatment — Incr. or Decr. from BL <10% Points, or No Change431
End of Treatment — LVEF<45% Points and Decr. from BL ≥10%-<15% Points2
End of Treatment — LVEF<45% Points and Decr. from BL ≥15% Points26
End of Treatment — LVEF≥45% Points and Decr. from BL ≥10% Points87
Day 28 of Follow-Up — Incr. or Decr. from BL <10% Points, or No Change472
Day 28 of Follow-Up — LVEF<45% Points and Decr. from BL ≥10%-<15% Points4
Day 28 of Follow-Up — LVEF<45% Points and Decr. from BL ≥15% Points22
Day 28 of Follow-Up — LVEF≥45% Points and Decr. from BL ≥10% Points86
PrimaryNumber of Participants With Laboratory Abnormalities in Hematology and Coagulation Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to NCI-CTC v4.0

Clinical laboratory tests for hematology and coagulation parameters were performed at local laboratories. Laboratory toxicities were defined based on NCI-CTC v4.0 from Grades 1 (least severe) to 4 (most severe). Some laboratory parameters are bi-dimensional (i.e. can be graded in both the low and high direction). These parameters were split and presented in both directions. Baseline was defined as the last non-missing measurement taken prior to the first dose of study treatment (including unscheduled assessments). Values from all visits, including unscheduled visits, were included in the derivation of the worst post-baseline grade. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: was clinically significant (per investigator); was accompanied by clinical symptoms; resulted in a change in study treatment; or resulted in a medical intervention or a change in concomitant therapy.

Time frame:
Predose at each treatment cycle (1 cycle is 3 weeks) from Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities in Hematology and Coagulation Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to NCI-CTC v4.0
ParticipantsPertuzumab + Trastuzumab + Taxane
Absolute Neutrophil Count: Normal to Normal844
Absolute Neutrophil Count: Normal to Grade 1232
Absolute Neutrophil Count: Normal to Grade 2169
Absolute Neutrophil Count: Normal to Grade 345
Absolute Neutrophil Count: Normal to Grade 427
Absolute Neutrophil Count: Normal to Missing27
Absolute Neutrophil Count: Grade 1 to Normal3
Absolute Neutrophil Count: Grade 1 to 111
Absolute Neutrophil Count: Grade 1 to 214
Absolute Neutrophil Count: Grade 1 to 33
Absolute Neutrophil Count: Grade 2 to 12
Absolute Neutrophil Count: Missing to Normal21
Absolute Neutrophil Count: Missing to Grade 12
Absolute Neutrophil Count: Missing to Grade 23
Absolute Neutrophil Count: Missing to Grade 41
Absolute Neutrophil Count: Missing to Missing32
Hemoglobin (High): Normal to Normal1327
Hemoglobin (High): Normal to Grade 129
Hemoglobin (High): Normal to Grade 31
Hemoglobin (High): Normal to Missing26
Hemoglobin (High): Grade 1 to Normal28
Hemoglobin (High): Grade 1 to 15
Hemoglobin (High): Grade 1 to Missing2
Hemoglobin (High): Grade 2 to Normal1
Hemoglobin (High): Missing to Normal14
Hemoglobin (High): Missing to Missing3
Hemoglobin (Low): Normal to Normal257
Hemoglobin (Low): Normal to Grade 1648
Hemoglobin (Low): Normal to Grade 2198
Hemoglobin (Low): Normal to Grade 310
Hemoglobin (Low): Normal to Missing21
Hemoglobin (Low): Grade 1 to Normal2
Hemoglobin (Low): Grade 1 to 1109
Hemoglobin (Low): Grade 1 to 2128
Hemoglobin (Low): Grade 1 to 312
Hemoglobin (Low): Grade 1 to Missing4
Hemoglobin (Low): Grade 2 to 15
Hemoglobin (Low): Grade 2 to 218
Hemoglobin (Low): Grade 2 to 33
Hemoglobin (Low): Grade 2 to Missing3
Hemoglobin (Low): Grade 3 to 11
Hemoglobin (Low): Missing to Normal3
Hemoglobin (Low): Missing to Grade 17
Hemoglobin (Low): Missing to Grade 24
Hemoglobin (Low): Missing to Missing3
Lymphocytes (High): Normal to Normal1251
Lymphocytes (High): Normal to Grade 2111
Lymphocytes (High): Normal to Grade 38
Lymphocytes (High): Normal to Missing28
Lymphocytes (High): Grade 2 to Normal4
Lymphocytes (High): Grade 2 to 210
Lymphocytes (High): Grade 2 to 32
Lymphocytes (High): Grade 3 to Normal1
Lymphocytes (High): Grade 3 to 32
Lymphocytes (High): Missing to Normal15
Lymphocytes (High): Missing to Grade 22
Lymphocytes (High): Missing to Missing2
Lymphocytes (Low): Normal to Normal565
Lymphocytes (Low): Normal to Grade 1255
Lymphocytes (Low): Normal to Grade 2210
Lymphocytes (Low): Normal to Grade 376
Lymphocytes (Low): Normal to Grade 418
Lymphocytes (Low): Normal to Missing19
Lymphocytes (Low): Grade 1 to Normal11
Lymphocytes (Low): Grade 1 to 154
Lymphocytes (Low): Grade 1 to 251
Lymphocytes (Low): Grade 1 to 318
Lymphocytes (Low): Grade 1 to 46
Lymphocytes (Low): Grade 1 to Missing5
Lymphocytes (Low): Grade 2 to Normal12
Lymphocytes (Low): Grade 2 to 18
Lymphocytes (Low): Grade 2 to 237
Lymphocytes (Low): Grade 2 to 319
Lymphocytes (Low): Grade 2 to 41
Lymphocytes (Low): Grade 2 to Missing2
Lymphocytes (Low): Grade 3 to 13
Lymphocytes (Low): Grade 3 to 28
Lymphocytes (Low): Grade 3 to 314
Lymphocytes (Low): Grade 3 to 42
Lymphocytes (Low): Grade 3 to Missing1
Lymphocytes (Low): Grade 4 to 21
Lymphocytes (Low): Grade 4 to 33
Lymphocytes (Low): Grade 4 to 416
Lymphocytes (Low): Grade 4 to Missing1
Lymphocytes (Low): Missing to Normal11
Lymphocytes (Low): Missing to Grade 13
Lymphocytes (Low): Missing to Grade 23
Lymphocytes (Low): Missing to Grade 31
Lymphocytes (Low): Missing to Missing2
Platelet Count: Normal to Normal1222
Platelet Count: Normal to Grade 1149
Platelet Count: Normal to Grade 31
Platelet Count: Normal to Grade 42
Platelet Count: Normal to Missing26
Platelet Count: Grade 1 to Normal15
Platelet Count: Grade 1 to 116
Platelet Count: Grade 1 to 21
Platelet Count: Grade 1 to Missing2
Platelet Count: Missing to Normal1
Platelet Count: Missing to Grade 11
White Blood Cells (High): Normal to Normal1391
White Blood Cells (High): Normal to Missing29
White Blood Cells (High): Missing to Normal14
White Blood Cells (High): Missing to Missing2
White Blood Cells (Low): Normal to Normal702
White Blood Cells (Low): Normal to Grade 1392
White Blood Cells (Low): Normal to Grade 2190
White Blood Cells (Low): Normal to Grade 329
White Blood Cells (Low): Normal to Grade 46
White Blood Cells (Low): Normal to Missing29
White Blood Cells (Low): Grade 1 to Normal4
White Blood Cells (Low): Grade 1 to 120
White Blood Cells (Low): Grade 1 to 233
White Blood Cells (Low): Grade 1 to 34
White Blood Cells (Low): Grade 2 to Normal2
White Blood Cells (Low): Grade 2 to 14
White Blood Cells (Low): Grade 2 to 23
White Blood Cells (Low): Grade 3 to Normal1
White Blood Cells (Low): Grade 3 to 31
White Blood Cells (Low): Missing to Normal9
White Blood Cells (Low): Missing to Grade 13
White Blood Cells (Low): Missing to Grade 21
White Blood Cells (Low): Missing to Grade 31
White Blood Cells (Low): Missing to Missing2
International Normalized Ratio: Normal to Normal17
International Normalized Ratio: Normal to Grade 152
International Normalized Ratio: Normal to Grade 21
International Normalized Ratio: Normal to Missing3
International Normalized Ratio: Grade 1 to Normal1
International Normalized Ratio: Grade 2 to 31
International Normalized Ratio: Missing to Normal424
International Normalized Ratio: Missing to Grade 1615
International Normalized Ratio: Missing to Grade 223
International Normalized Ratio: Missing to Grade 314
International Normalized Ratio: Missing to Missing285
PrimaryNumber of Participants With Laboratory Abnormalities in Hematology and Coagulation Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to Normal Range Criteria

Clinical laboratory tests for hematology and coagulation parameters were performed at local laboratories. Laboratory toxicities were defined based on local laboratory normal ranges (for parameters with NCI-CTC grade not defined). Some laboratory parameters are bi-dimensional (i.e. can be graded in both the low and high direction). These parameters were split and presented in both directions. Baseline was defined as the last non-missing measurement taken prior to the first dose of study treatment (including unscheduled assessments). Values from all visits, including unscheduled visits, were included in the derivation of the worst post-baseline grade. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: was clinically significant (per investigator); was accompanied by clinical symptoms; resulted in a change in study treatment; or resulted in a medical intervention or a change in concomitant therapy.

Time frame:
Predose at each treatment cycle (1 cycle is 3 weeks) from Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities in Hematology and Coagulation Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to Normal Range Criteria
ParticipantsPertuzumab + Trastuzumab + Taxane
Basophils (High): Normal to Normal1020
Basophils (High): Normal to Low3
Basophils (High): Normal to High261
Basophils (High): Low to Normal16
Basophils (High): Low to Low1
Basophils (High): Low to High5
Basophils (High): High to Normal11
Basophils (High): High to High38
Basophils (High): Missing to Normal21
Basophils (High): Missing to High7
Basophils (High): Missing to Missing53
Basophils (Low): Normal to Normal1206
Basophils (Low): Normal to Low77
Basophils (Low): Normal to High1
Basophils (Low): Low to Normal3
Basophils (Low): Low to Low18
Basophils (Low): Low to Missing1
Basophils (Low): High to Normal36
Basophils (Low): High to Low5
Basophils (Low): High to High8
Basophils (Low): Missing to Normal40
Basophils (Low): Missing to Low3
Basophils (Low): Missing to High1
Basophils (Low): Missing to Missing37
Eosinophils (High): Normal to Normal904
Eosinophils (High): Normal to Low13
Eosinophils (High): Normal to High283
Eosinophils (High): Low to Normal66
Eosinophils (High): Low to Low13
Eosinophils (High): Low to High36
Eosinophils (High): High to Normal11
Eosinophils (High): High to High35
Eosinophils (High): Missing to Normal17
Eosinophils (High): Missing to Low1
Eosinophils (High): Missing to High7
Eosinophils (High): Missing to Missing50
Eosinophils (Low): Normal to Normal810
Eosinophils (Low): Normal to Low390
Eosinophils (Low): Low to Normal13
Eosinophils (Low): Low to Low101
Eosinophils (Low): Low to High1
Eosinophils (Low): High to Normal28
Eosinophils (Low): High to Low13
Eosinophils (Low): High to High5
Eosinophils (Low): Missing to Normal37
Eosinophils (Low): Missing to Low10
Eosinophils (Low): Missing to Missing28
Hematocrit (High): Normal to Normal953
Hematocrit (High): Normal to Low47
Hematocrit (High): Normal to High58
Hematocrit (High): Normal to Missing4
Hematocrit (High): Low to Normal201
Hematocrit (High): Low to Low97
Hematocrit (High): Low to High10
Hematocrit (High): Low to Missing2
Hematocrit (High): High to Normal17
Hematocrit (High): High to High12
Hematocrit (High): Missing to Normal15
Hematocrit (High): Missing to High1
Hematocrit (High): Missing to Missing19
Hematocrit (Low): Normal to Normal223
Hematocrit (Low): Normal to Low837
Hematocrit (Low): Normal to Missing2
Hematocrit (Low): Low to Normal5
Hematocrit (Low): Low to Low305
Hematocrit (Low): High to Normal13
Hematocrit (Low): High to Low16
Hematocrit (Low): Missing to Normal3
Hematocrit (Low): Missing to Low12
Hematocrit (Low): Missing to Missing20
Monocytes (High): Normal to Normal802
Monocytes (High): Normal to Low3
Monocytes (High): Normal to High365
Monocytes (High): Low to Normal58
Monocytes (High): Low to Low6
Monocytes (High): Low to High17
Monocytes (High): High to Normal29
Monocytes (High): High to Low1
Monocytes (High): High to High82
Monocytes (High): Missing to Normal12
Monocytes (High): Missing to High8
Monocytes (High): Missing to Missing53
Monocytes (Low): Normal to Normal747
Monocytes (Low): Normal to Low420
Monocytes (Low): Normal to High3
Monocytes (Low): Low to Normal11
Monocytes (Low): Low to Low70
Monocytes (Low): High to Normal64
Monocytes (Low): High to Low40
Monocytes (Low): High to High8
Monocytes (Low): Missing to Normal13
Monocytes (Low): Missing to Low10
Monocytes (Low): Missing to High5
Monocytes (Low): Missing to Missing45
Red Blood Cells (High): Normal to Normal975
Red Blood Cells (High): Normal to Low31
Red Blood Cells (High): Normal to High111
Red Blood Cells (High): Low to Normal131
Red Blood Cells (High): Low to Low61
Red Blood Cells (High): Low to High15
Red Blood Cells (High): High to Normal22
Red Blood Cells (High): High to High45
Red Blood Cells (High): Missing to Normal18
Red Blood Cells (High): Missing to Low2
Red Blood Cells (High): Missing to High2
Red Blood Cells (High): Missing to Missing23
Red Blood Cells (Low): Normal to Normal350
Red Blood Cells (Low): Normal to Low767
Red Blood Cells (Low): Low to Normal10
Red Blood Cells (Low): Low to Low197
Red Blood Cells (Low): High to Normal44
Red Blood Cells (Low): High to Low21
Red Blood Cells (Low): High to High2
Red Blood Cells (Low): Missing to Normal6
Red Blood Cells (Low): Missing to Low16
Red Blood Cells (Low): Missing to Missing23
PTT (High): Normal to Normal46
PTT (High): Normal to Low1
PTT (High): Normal to High15
PTT (High): Low to Normal19
PTT (High): Low to Low1
PTT (High): Low to High1
PTT (High): High to High1
PTT (High): Missing to Normal19
PTT (High): Missing to Low5
PTT (High): Missing to High9
PTT (High): Missing to Missing1319
PTT (Low): Normal to Normal46
PTT (Low): Normal to Low16
PTT (Low): Low to Normal3
PTT (Low): Low to Low18
PTT (Low): High to Normal1
PTT (Low): Missing to Normal20
PTT (Low): Missing to Low6
PTT (Low): Missing to High5
PTT (Low): Missing to Missing1321
PrimaryNumber of Participants With Laboratory Abnormalities in Biochemistry Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to NCI-CTC v4.0

Clinical laboratory tests for biochemistry parameters were performed at local laboratories. Laboratory toxicities were defined based on NCI-CTC v4.0 from Grades 1 (least severe) to 4 (most severe). Some laboratory parameters are bi-dimensional (i.e. can be graded in both the low and high direction). These parameters were split and presented in both directions. Baseline was defined as the last non-missing measurement taken prior to the first dose of study treatment (including unscheduled assessments). Values from all visits, including unscheduled visits, were included in the derivation of the worst post-baseline grade. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: was clinically significant (per investigator); was accompanied by clinical symptoms; resulted in a change in study treatment; or resulted in a medical intervention or a change in concomitant therapy.

Time frame:
Predose at each treatment cycle (1 cycle is 3 weeks) from Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities in Biochemistry Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to NCI-CTC v4.0
ParticipantsPertuzumab + Trastuzumab + Taxane
Alanine Aminotransferase: Normal to Normal610
Alanine Aminotransferase: Normal to Grade 1425
Alanine Aminotransferase: Normal to Grade 226
Alanine Aminotransferase: Normal to Grade 319
Alanine Aminotransferase: Normal to Missing25
Alanine Aminotransferase: Grade 1 to Normal75
Alanine Aminotransferase: Grade 1 to 1151
Alanine Aminotransferase: Grade 1 to 226
Alanine Aminotransferase: Grade 1 to 314
Alanine Aminotransferase: Grade 1 to Missing6
Alanine Aminotransferase: Grade 2 to Normal8
Alanine Aminotransferase: Grade 2 to 128
Alanine Aminotransferase: Grade 2 to 25
Alanine Aminotransferase: Grade 2 to 31
Alanine Aminotransferase: Grade 3 to 12
Alanine Aminotransferase: Missing to Normal7
Alanine Aminotransferase: Missing to Grade 14
Alanine Aminotransferase: Missing to Grade 21
Alanine Aminotransferase: Missing to Missing3
Aspartate Aminotransferase: Normal to Normal562
Aspartate Aminotransferase: Normal to Grade 1386
Aspartate Aminotransferase: Normal to Grade 222
Aspartate Aminotransferase: Normal to Grade 39
Aspartate Aminotransferase: Normal to Missing15
Aspartate Aminotransferase: Grade 1 to Normal120
Aspartate Aminotransferase: Grade 1 to 1187
Aspartate Aminotransferase: Grade 1 to 224
Aspartate Aminotransferase: Grade 1 to 39
Aspartate Aminotransferase: Grade 1 to Missing14
Aspartate Aminotransferase: Grade 2 to Normal13
Aspartate Aminotransferase: Grade 2 to 129
Aspartate Aminotransferase: Grade 2 to 23
Aspartate Aminotransferase: Grade 2 to Missing3
Aspartate Aminotransferase: Grade 3 to Normal2
Aspartate Aminotransferase: Grade 3 to 17
Aspartate Aminotransferase: Grade 3 to Missing1
Aspartate Aminotransferase: Missing to Normal13
Aspartate Aminotransferase: Missing to Grade 19
Aspartate Aminotransferase: Missing to Grade 22
Aspartate Aminotransferase: Missing to Missing6
Albumin: Normal to Normal785
Albumin: Normal to Grade 1357
Albumin: Normal to Grade 286
Albumin: Normal to Grade 310
Albumin: Normal to Missing23
Albumin: Grade 1 to Normal13
Albumin: Grade 1 to 143
Albumin: Grade 1 to 235
Albumin: Grade 1 to 31
Albumin: Grade 1 to Missing7
Albumin: Grade 2 to Normal3
Albumin: Grade 2 to 15
Albumin: Grade 2 to 28
Albumin: Grade 2 to 32
Albumin: Grade 2 to Missing2
Albumin: Grade 3 to 21
Albumin: Grade 3 to Missing1
Albumin: Missing to Normal28
Albumin: Missing to Grade 114
Albumin: Missing to Grade 26
Albumin: Missing to Missing6
Alkaline Phosphatase: Normal to Normal605
Alkaline Phosphatase: Normal to Grade 1329
Alkaline Phosphatase: Normal to Grade 214
Alkaline Phosphatase: Normal to Grade 32
Alkaline Phosphatase: Normal to Missing18
Alkaline Phosphatase: Grade 1 to Normal44
Alkaline Phosphatase: Grade 1 to 1241
Alkaline Phosphatase: Grade 1 to 272
Alkaline Phosphatase: Grade 1 to 315
Alkaline Phosphatase: Grade 1 to Missing6
Alkaline Phosphatase: Grade 2 to Normal2
Alkaline Phosphatase: Grade 2 to 121
Alkaline Phosphatase: Grade 2 to 224
Alkaline Phosphatase: Grade 2 to 314
Alkaline Phosphatase: Grade 2 to Missing8
Alkaline Phosphatase: Grade 3 to 12
Alkaline Phosphatase: Grade 3 to 21
Alkaline Phosphatase: Grade 3 to 34
Alkaline Phosphatase: Missing to Normal7
Alkaline Phosphatase: Missing to Grade 13
Alkaline Phosphatase: Missing to Grade 31
Alkaline Phosphatase: Missing to Missing3
Calcium (High): Normal to Normal1060
Calcium (High): Normal to Grade 1192
Calcium (High): Normal to Grade 22
Calcium (High): Normal to Grade 31
Calcium (High): Normal to Grade 41
Calcium (High): Normal to Missing26
Calcium (High): Grade 1 to Normal47
Calcium (High): Grade 1 to 147
Calcium (High): Grade 1 to 21
Calcium (High): Grade 1 to 31
Calcium (High): Grade 1 to Missing5
Calcium (High): Grade 2 to Normal1
Calcium (High): Grade 2 to 11
Calcium (High): Grade 2 to 21
Calcium (High): Grade 3 to Normal2
Calcium (High): Grade 3 to 11
Calcium (High): Grade 3 to 21
Calcium (High): Grade 4 to Normal1
Calcium (High): Missing to Normal32
Calcium (High): Missing to Grade 13
Calcium (High): Missing to Missing10
Calcium (Low): Normal to Normal786
Calcium (Low): Normal to Grade 1378
Calcium (Low): Normal to Grade 2117
Calcium (Low): Normal to Grade 318
Calcium (Low): Normal to Missing30
Calcium (Low): Grade 1 to Normal5
Calcium (Low): Grade 1 to 131
Calcium (Low): Grade 1 to 212
Calcium (Low): Grade 1 to 32
Calcium (Low): Grade 1 to Missing1
Calcium (Low): Grade 2 to Normal5
Calcium (Low): Grade 2 to 11
Calcium (Low): Grade 2 to 24
Calcium (Low): Grade 3 to 31
Calcium (Low): Missing to Normal20
Calcium (Low): Missing to Grade 111
Calcium (Low): Missing to Grade 24
Calcium (Low): Missing to Missing10
Creatinine: Normal to Normal176
Creatinine: Normal to Grade 1960
Creatinine: Normal to Grade 2175
Creatinine: Normal to Grade 35
Creatinine: Normal to Grade 45
Creatinine: Normal to Missing26
Creatinine: Grade 1 to Normal12
Creatinine: Grade 1 to 138
Creatinine: Grade 1 to 28
Creatinine: Grade 1 to Missing3
Creatinine: Grade 2 to 23
Creatinine: Grade 2 to 31
Creatinine: Grade 2 to Missing1
Creatinine: Missing to Normal11
Creatinine: Missing to Grade 16
Creatinine: Missing to Missing6
Gamma-Glutamyl Transpeptidase: Normal to Normal498
Gamma-Glutamyl Transpeptidase: Normal to Grade 1227
Gamma-Glutamyl Transpeptidase: Normal to Grade 239
Gamma-Glutamyl Transpeptidase: Normal to Grade 315
Gamma-Glutamyl Transpeptidase: Normal to Missing12
Gamma-Glutamyl Transpeptidase: Grade 1 to Normal64
Gamma-Glutamyl Transpeptidase: Grade 1 to 1187
Gamma-Glutamyl Transpeptidase: Grade 1 to 275
Gamma-Glutamyl Transpeptidase: Grade 1 to 320
Gamma-Glutamyl Transpeptidase: Grade 1 to Missing7
Gamma-Glutamyl Transpeptidase: Grade 2 to Normal5
Gamma-Glutamyl Transpeptidase: Grade 2 to 152
Gamma-Glutamyl Transpeptidase: Grade 2 to 245
Gamma-Glutamyl Transpeptidase: Grade 2 to 321
Gamma-Glutamyl Transpeptidase: Grade 2 to Missing5
Gamma-Glutamyl Transpeptidase: Grade 3 to Normal2
Gamma-Glutamyl Transpeptidase: Grade 3 to 115
Gamma-Glutamyl Transpeptidase: Grade 3 to 238
Gamma-Glutamyl Transpeptidase: Grade 3 to 347
Gamma-Glutamyl Transpeptidase: Grade 3 to Missing4
Gamma-Glutamyl Transpeptidase: Missing to Normal14
Gamma-Glutamyl Transpeptidase: Missing to Grade 17
Gamma-Glutamyl Transpeptidase: Missing to Grade 210
Gamma-Glutamyl Transpeptidase: Missing to Grade 318
Gamma-Glutamyl Transpeptidase: Missing to Missing9
Glucose (High): Normal to Normal340
Glucose (High): Normal to Grade 1534
Glucose (High): Normal to Grade 2115
Glucose (High): Normal to Missing21
Glucose (High): Grade 1 to Normal28
Glucose (High): Grade 1 to 1190
Glucose (High): Grade 1 to 274
Glucose (High): Grade 1 to Missing9
Glucose (High): Grade 2 to Normal2
Glucose (High): Grade 2 to 113
Glucose (High): Grade 2 to 210
Glucose (High): Grade 2 to Missing3
Glucose (High): Missing to Normal20
Glucose (High): Missing to Grade 130
Glucose (High): Missing to Grade 240
Glucose (High): Missing to Missing7
Glucose (Low): Normal to Normal1061
Glucose (Low): Normal to Grade 1173
Glucose (Low): Normal to Grade 219
Glucose (Low): Normal to Grade 34
Glucose (Low): Normal to Grade 45
Glucose (Low): Normal to Missing33
Glucose (Low): Grade 1 to Normal8
Glucose (Low): Grade 1 to 124
Glucose (Low): Grade 1 to 23
Glucose (Low): Grade 1 to 31
Glucose (Low): Grade 1 to 41
Glucose (Low): Grade 2 to Normal1
Glucose (Low): Missing to Normal69
Glucose (Low): Missing to Grade 116
Glucose (Low): Missing to Grade 22
Glucose (Low): Missing to Grade 31
Glucose (Low): Missing to Missing15
Magnesium (High): Normal to Normal1100
Magnesium (High): Normal to Grade 1122
Magnesium (High): Normal to Grade 338
Magnesium (High): Normal to Grade 46
Magnesium (High): Normal to Missing31
Magnesium (High): Grade 1 to Normal12
Magnesium (High): Grade 1 to 17
Magnesium (High): Grade 3 to Normal2
Magnesium (High): Grade 3 to 32
Magnesium (High): Grade 4 to Normal1
Magnesium (High): Grade 4 to 41
Magnesium (High): Missing to Normal85
Magnesium (High): Missing to Grade 112
Magnesium (High): Missing to Grade 36
Magnesium (High): Missing to Missing11
Magnesium (Low): Normal to Normal857
Magnesium (Low): Normal to Grade 1319
Magnesium (Low): Normal to Grade 228
Magnesium (Low): Normal to Grade 39
Magnesium (Low): Normal to Grade 43
Magnesium (Low): Normal to Missing28
Magnesium (Low): Grade 1 to Normal9
Magnesium (Low): Grade 1 to 155
Magnesium (Low): Grade 1 to 27
Magnesium (Low): Grade 1 to 33
Magnesium (Low): Grade 1 to Missing3
Magnesium (Low): Grade 4 to 41
Magnesium (Low): Missing to Normal81
Magnesium (Low): Missing to Grade 119
Magnesium (Low): Missing to Grade 21
Magnesium (Low): Missing to Grade 31
Magnesium (Low): Missing to Grade 41
Magnesium (Low): Missing to Missing11
Potassium (High): Normal to Normal1051
Potassium (High): Normal to Grade 1183
Potassium (High): Normal to Grade 281
Potassium (High): Normal to Grade 318
Potassium (High): Normal to Grade 48
Potassium (High): Normal to Missing26
Potassium (High): Grade 1 to Normal16
Potassium (High): Grade 1 to 18
Potassium (High): Grade 1 to 27
Potassium (High): Grade 1 to 31
Potassium (High): Grade 1 to Missing3
Potassium (High): Grade 2 to Normal2
Potassium (High): Grade 2 to 11
Potassium (High): Grade 2 to 21
Potassium (High): Grade 4 to Normal1
Potassium (High): Missing to Normal18
Potassium (High): Missing to Grade 15
Potassium (High): Missing to Grade 23
Potassium (High): Missing to Missing3
Potassium (Low): Normal to Normal990
Potassium (Low): Normal to Grade 2367
Potassium (Low): Normal to Missing29
Potassium (Low): Grade 2 to Normal8
Potassium (Low): Grade 2 to 213
Potassium (Low): Missing to Normal19
Potassium (Low): Missing to Grade 27
Potassium (Low): Missing to Missing3
Sodium (High): Normal to Normal1075
Sodium (High): Normal to Grade 1256
Sodium (High): Normal to Grade 236
Sodium (High): Normal to Grade 39
Sodium (High): Normal to Grade 41
Sodium (High): Normal to Missing28
Sodium (High): Grade 1 to Normal3
Sodium (High): Grade 1 to 16
Sodium (High): Grade 1 to 23
Sodium (High): Grade 1 to 31
Sodium (High): Grade 2 to 22
Sodium (High): Grade 2 to 31
Sodium (High): Grade 3 to Normal1
Sodium (High): Grade 3 to Missing1
Sodium (High): Missing to Normal11
Sodium (High): Missing to Grade 11
Sodium (High): Missing to Missing1
Sodium (Low): Normal to Normal994
Sodium (Low): Normal to Grade 1298
Sodium (Low): Normal to Grade 320
Sodium (Low): Normal to Grade 415
Sodium (Low): Normal to Missing23
Sodium (Low): Grade 1 to Normal21
Sodium (Low): Grade 1 to 136
Sodium (Low): Grade 1 to 32
Sodium (Low): Grade 1 to 41
Sodium (Low): Grade 1 to Missing6
Sodium (Low): Grade 3 to Normal1
Sodium (Low): Grade 3 to 12
Sodium (Low): Grade 3 to 31
Sodium (Low): Grade 4 to Normal2
Sodium (Low): Grade 4 to 11
Sodium (Low): Missing to Normal6
Sodium (Low): Missing to Grade 15
Sodium (Low): Missing to Grade 31
Sodium (Low): Missing to Missing1
Total Bilirubin: Normal to Normal1231
Total Bilirubin: Normal to Grade 188
Total Bilirubin: Normal to Grade 235
Total Bilirubin: Normal to Grade 32
Total Bilirubin: Normal to Missing28
Total Bilirubin: Grade 1 to Normal3
Total Bilirubin: Grade 1 to 111
Total Bilirubin: Grade 1 to 26
Total Bilirubin: Grade 1 to Missing2
Total Bilirubin: Grade 2 to 11
Total Bilirubin: Grade 2 to 21
Total Bilirubin: Grade 2 to Missing1
Total Bilirubin: Grade 3 to Normal1
Total Bilirubin: Missing to Normal22
Total Bilirubin: Missing to Grade 21
Total Bilirubin: Missing to Missing3
Uric Acid: Normal to Normal933
Uric Acid: Normal to Grade 1190
Uric Acid: Normal to Grade 48
Uric Acid: Normal to Missing20
Uric Acid: Grade 1 to Normal58
Uric Acid: Grade 1 to 1120
Uric Acid: Grade 1 to 46
Uric Acid: Grade 1 to Missing11
Uric Acid: Grade 4 to Normal1
Uric Acid: Grade 4 to 12
Uric Acid: Grade 4 to 44
Uric Acid: Grade 4 to Missing1
Uric Acid: Missing to Normal57
Uric Acid: Missing to Grade 113
Uric Acid: Missing to Grade 42
Uric Acid: Missing to Missing10
PrimaryNumber of Participants With Laboratory Abnormalities in Biochemistry Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to Normal Range Criteria

Clinical laboratory tests for biochemistry parameters were performed at local laboratories. Laboratory toxicities were defined based on local laboratory normal ranges (for parameters with NCI-CTC grade not defined). Some laboratory parameters are bi-dimensional (i.e. can be graded in both the low and high direction). These parameters were split and presented in both directions. Baseline was defined as the last non-missing measurement taken prior to the first dose of study treatment (including unscheduled assessments). Values from all visits, including unscheduled visits, were included in the derivation of the worst post-baseline grade. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: was clinically significant (per investigator); was accompanied by clinical symptoms; resulted in a change in study treatment; or resulted in a medical intervention or a change in concomitant therapy.

Time frame:
Predose at each treatment cycle (1 cycle is 3 weeks) from Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities in Biochemistry Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to Normal Range Criteria
ParticipantsPertuzumab + Trastuzumab + Taxane
Blood Urea Nitrogen (High): Normal to Normal717
Blood Urea Nitrogen (High): Normal to Low5
Blood Urea Nitrogen (High): Normal to High402
Blood Urea Nitrogen (High): Normal to Missing2
Blood Urea Nitrogen (High): Low to Normal69
Blood Urea Nitrogen (High): Low to Low8
Blood Urea Nitrogen (High): Low to High12
Blood Urea Nitrogen (High): High to Normal23
Blood Urea Nitrogen (High): High to High98
Blood Urea Nitrogen (High): Missing to Normal42
Blood Urea Nitrogen (High): Missing to High19
Blood Urea Nitrogen (High): Missing to Missing39
Blood Urea Nitrogen (Low): Normal to Normal828
Blood Urea Nitrogen (Low): Normal to Low293
Blood Urea Nitrogen (Low): Normal to High3
Blood Urea Nitrogen (Low): Normal to Missing2
Blood Urea Nitrogen (Low): Low to Normal17
Blood Urea Nitrogen (Low): Low to Low72
Blood Urea Nitrogen (Low): High to Normal104
Blood Urea Nitrogen (Low): High to Low11
Blood Urea Nitrogen (Low): High to High6
Blood Urea Nitrogen (Low): Missing to Normal47
Blood Urea Nitrogen (Low): Missing to Low11
Blood Urea Nitrogen (Low): Missing to High3
Blood Urea Nitrogen (Low): Missing to Missing39
Calc Creatinine Clearance (High): Normal to Normal540
Calc Creatinine Clearance (High): Normal to Low11
Calc Creatinine Clearance (High): Normal to High201
Calc Creatinine Clearance(High): Normal to Missing2
Calc Creatinine Clearance (High): Low to Normal166
Calc Creatinine Clearance (High): Low to Low107
Calc Creatinine Clearance (High): Low to High34
Calc Creatinine Clearance (High): Low to Missing1
Calc Creatinine Clearance (High): High to Normal13
Calc Creatinine Clearance (High): High to High101
Calc Creatinine Clearance(High): Missing to Normal46
Calc Creatinine Clearance (High): Missing to Low8
Calc Creatinine Clearance (High): Missing to High11
Calc Creatinine Clearance(High):Missing to Missing195
Calc Creatinine Clearance (Low): Normal to Normal393
Calc Creatinine Clearance (Low): Normal to Low353
Calc Creatinine Clearance (Low): Normal to High8
Calc Creatinine Clearance (Low): Low to Normal12
Calc Creatinine Clearance (Low): Low to Low294
Calc Creatinine Clearance (Low): Low to High1
Calc Creatinine Clearance (Low): Low to Missing1
Calc Creatinine Clearance (Low): High to Normal61
Calc Creatinine Clearance (Low): High to Low36
Calc Creatinine Clearance (Low): High to High17
Calc Creatinine Clearance (Low): Missing to Normal66
Calc Creatinine Clearance (Low): Missing to Low44
Calc Creatinine Clearance (Low): Missing to High17
Calc Creatinine Clearance(Low): Missing to Missing133
Chloride (High): Normal to Normal665
Chloride (High): Normal to Low2
Chloride (High): Normal to High508
Chloride (High): Low to Normal54
Chloride (High): Low to High13
Chloride (High): High to Normal4
Chloride (High): High to High58
Chloride (High): Missing to Normal41
Chloride (High): Missing to High32
Chloride (High): Missing to Missing59
Chloride (Low): Normal to Normal971
Chloride (Low): Normal to Low201
Chloride (Low): Normal to High3
Chloride (Low): Low to Normal31
Chloride (Low): Low to Low36
Chloride (Low): High to Normal57
Chloride (Low): High to Low4
Chloride (Low): High to High1
Chloride (Low): Missing to Normal60
Chloride (Low): Missing to Low13
Chloride (Low): Missing to High1
Chloride (Low): Missing to Missing58
Lactate Dehydrogenase (High): Normal to Normal328
Lactate Dehydrogenase (High): Normal to High499
Lactate Dehydrogenase (High): Low to Normal10
Lactate Dehydrogenase (High): Low to Low1
Lactate Dehydrogenase (High): Low to High4
Lactate Dehydrogenase (High): High to Normal74
Lactate Dehydrogenase (High): High to High449
Lactate Dehydrogenase (High): Missing to Normal16
Lactate Dehydrogenase (High): Missing to High30
Lactate Dehydrogenase (High): Missing to Missing25
Lactate Dehydrogenase (Low): Normal to Normal716
Lactate Dehydrogenase (Low): Normal to Low102
Lactate Dehydrogenase (Low): Normal to High9
Lactate Dehydrogenase (Low): Low to Normal5
Lactate Dehydrogenase (Low): Low to Low9
Lactate Dehydrogenase (Low): Low to High1
Lactate Dehydrogenase (Low): High to Normal426
Lactate Dehydrogenase (Low): High to Low31
Lactate Dehydrogenase (Low): High to High66
Lactate Dehydrogenase (Low): Missing to Normal39
Lactate Dehydrogenase (Low): Missing to Low3
Lactate Dehydrogenase (Low): Missing to High3
Lactate Dehydrogenase (Low): Missing to Missing26
Total Protein (High): Normal to Normal1091
Total Protein (High): Normal to Low20
Total Protein (High): Normal to High110
Total Protein (High): Low to Normal72
Total Protein (High): Low to Low14
Total Protein (High): High to Normal28
Total Protein (High): High to High24
Total Protein (High): Missing to Normal38
Total Protein (High): Missing to Low3
Total Protein (High): Missing to High4
Total Protein (High): Missing to Missing32
Total Protein (Low): Normal to Normal530
Total Protein (Low): Normal to Low691
Total Protein (Low): Low to Normal4
Total Protein (Low): Low to Low82
Total Protein (Low): High to Normal41
Total Protein (Low): High to Low11
Total Protein (Low): Missing to Normal23
Total Protein (Low): Missing to Low23
Total Protein (Low): Missing to Missing31
SecondaryProgression-Free Survival, as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.

Time frame:
From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Median · Months
Progression-Free Survival, as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
MonthsPertuzumab + Trastuzumab + Taxane
Progression-Free Survival, as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)20.67 (18.89 to 23.13)
SecondarySubgroup Analysis by Region of Enrollment: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1

Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.

Time frame:
From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Median · Months
Subgroup Analysis by Region of Enrollment: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
MonthsEuropeAsiaNorth AmericaSouth AmericaAfricaOther (Australia)
Subgroup Analysis by Region of Enrollment: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.119.38 (17.51 to 21.75)23.79 (15.90 to 28.85)25.17 (14.42 to 29.44)22.37 (17.51 to 32.72)22.83 (12.02 to 27.86)NA (15.74 to NA)
SecondarySubgroup Analysis by Age (≤65 vs. >65 Years): Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1

Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.

Time frame:
From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Median · Months
Subgroup Analysis by Age (≤65 vs. >65 Years): Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
MonthsAge ≤65 YearsAge >65 Years
Subgroup Analysis by Age (≤65 vs. >65 Years): Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.121.98 (19.65 to 24.25)14.72 (12.22 to 19.55)
SecondarySubgroup Analysis by ECOG Performance Status at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1

Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.

Time frame:
From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Median · Months
Subgroup Analysis by ECOG Performance Status at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
MonthsECOG Performance Status 0 or 1ECOG Performance Status 2
Subgroup Analysis by ECOG Performance Status at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.121.49 (19.45 to 23.98)12.88 (8.67 to 15.90)
SecondarySubgroup Analysis by Taxane Chemotherapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1

Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.

Time frame:
From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Median · Months
Subgroup Analysis by Taxane Chemotherapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
MonthsDocetaxelPaclitaxelNab-Paclitaxel
Subgroup Analysis by Taxane Chemotherapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.119.38 (16.92 to 22.11)23.23 (19.58 to 25.59)19.22 (11.70 to 37.09)
SecondarySubgroup Analysis by Visceral Disease at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1

Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.

Time frame:
From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Median · Months
Subgroup Analysis by Visceral Disease at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
MonthsVisceral DiseaseNon-Visceral Disease
Subgroup Analysis by Visceral Disease at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.118.23 (16.13 to 20.57)27.24 (23.75 to 34.40)
SecondarySubgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1

Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.

Time frame:
From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Median · Months
Subgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
MonthsPrior (Neo)Adjuvant ChemotherapyNo Prior (Neo)Adjuvant Chemotherapy
Subgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.119.12 (16.59 to 21.49)23.49 (20.57 to 25.63)
SecondarySubgroup Analysis by Hormone Receptor Status at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1

Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.

Time frame:
From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Median · Months
Subgroup Analysis by Hormone Receptor Status at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
MonthsHormone Receptor PositiveHormone Receptor NegativeHormone Receptor Status Unknown
Subgroup Analysis by Hormone Receptor Status at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.120.60 (18.53 to 23.82)20.73 (17.05 to 23.79)32.13 (11.63 to 61.57)
SecondarySubgroup Analysis by Previous Trastuzumab Therapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1

Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.

Time frame:
From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Median · Months
Subgroup Analysis by Previous Trastuzumab Therapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
MonthsPrevious Trastuzumab TherapyNo Previous Trastuzumab Therapy
Subgroup Analysis by Previous Trastuzumab Therapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.115.38 (13.67 to 19.02)23.39 (20.67 to 25.00)
SecondaryOverall Survival

Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.

Time frame:
From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Median · Months
Overall Survival
MonthsPertuzumab + Trastuzumab + Taxane
Overall Survival65.31 (60.88 to 70.87)
SecondarySubgroup Analysis by Region of Enrollment: Overall Survival

Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.

Time frame:
From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Median · Months
Subgroup Analysis by Region of Enrollment: Overall Survival
MonthsEuropeAsiaNorth AmericaSouth AmericaAfricaOther (Australia)
Subgroup Analysis by Region of Enrollment: Overall Survival66.56 (61.90 to 73.49)63.57 (47.57 to NA)55.56 (41.49 to NA)NA (49.84 to NA)53.22 (33.35 to 63.87)NA (44.16 to NA)
SecondarySubgroup Analysis by Age (≤65 vs. >65 Years): Overall Survival

Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.

Time frame:
From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Median · Months
Subgroup Analysis by Age (≤65 vs. >65 Years): Overall Survival
MonthsAge ≤65 YearsAge >65 Years
Subgroup Analysis by Age (≤65 vs. >65 Years): Overall Survival70.01 (64.33 to 81.08)50.10 (41.26 to 53.98)
SecondarySubgroup Analysis by ECOG Performance Status at Baseline: Overall Survival

Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.

Time frame:
From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Median · Months
Subgroup Analysis by ECOG Performance Status at Baseline: Overall Survival
MonthsECOG Performance Status 0 or 1ECOG Performance Status 2
Subgroup Analysis by ECOG Performance Status at Baseline: Overall Survival67.25 (63.44 to 76.52)31.15 (20.50 to 39.13)
SecondarySubgroup Analysis by Taxane Chemotherapy: Overall Survival

Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.

Time frame:
From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Median · Months
Subgroup Analysis by Taxane Chemotherapy: Overall Survival
MonthsDocetaxelPaclitaxelNab-Paclitaxel
Subgroup Analysis by Taxane Chemotherapy: Overall Survival66.53 (61.67 to 77.27)64.03 (56.61 to 72.25)70.87 (39.69 to NA)
SecondarySubgroup Analysis by Visceral Disease at Baseline: Overall Survival

Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.

Time frame:
From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Median · Months
Subgroup Analysis by Visceral Disease at Baseline: Overall Survival
MonthsVisceral DiseaseNon-Visceral Disease
Subgroup Analysis by Visceral Disease at Baseline: Overall Survival57.10 (52.40 to 63.44)81.08 (71.66 to NA)
SecondarySubgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Overall Survival

Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.

Time frame:
From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Median · Months
Subgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Overall Survival
MonthsPrior (Neo)Adjuvant ChemotherapyNo Prior (Neo)Adjuvant Chemotherapy
Subgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Overall Survival57.10 (51.06 to 62.82)79.80 (71.79 to NA)
SecondarySubgroup Analysis by Hormone Receptor Status at Baseline: Overall Survival

Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.

Time frame:
From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Median · Months
Subgroup Analysis by Hormone Receptor Status at Baseline: Overall Survival
MonthsHormone Receptor PositiveHormone Receptor NegativeHormone Receptor Status Unknown
Subgroup Analysis by Hormone Receptor Status at Baseline: Overall Survival66.66 (62.39 to 77.27)60.19 (52.34 to 67.71)NA (16.13 to NA)
SecondarySubgroup Analysis by Previous Trastuzumab Therapy: Overall Survival

Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.

Time frame:
From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Median · Months
Subgroup Analysis by Previous Trastuzumab Therapy: Overall Survival
MonthsPrevious Trastuzumab TherapyNo Previous Trastuzumab Therapy
Subgroup Analysis by Previous Trastuzumab Therapy: Overall Survival54.08 (48.66 to 60.75)73.50 (65.61 to NA)
SecondaryOverall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.1

The overall response rate was defined as the percentage of participants with complete response (CR) or partial response (PR) as their best confirmed response (≥4 weeks later), as assessed by the investigator using RECIST v1.1 from the start of study treatment until disease progression/recurrence or death. Responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants without post-baseline tumor assessments were considered non-responders.

Time frame:
Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression or death. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Number · Percentage of participants
Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.1
Percentage of participantsPertuzumab + Trastuzumab + Taxane
Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.179.5 (77.07 to 81.72)
SecondaryPercentage of Participants by Best Overall Response as Assessed by the Investigator Using RECIST v1.1

Best overall response (BOR) was defined as the best response recorded from the first dose of study treatment until disease progression/recurrence or death in the absence of disease progression. The hierarchy used to determine BOR: Complete Response (CR)\>Partial Response (PR)\>Stable Disease (SD)\>Progressive Disease (PD)\>Not Evaluable. Note that CR or PR was confirmed ≥4 weeks later. RECIST v1.1 responses are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum.; PD = At least 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study, and absolute increase of ≥5 mm.; SD = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression or death. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Number · Percentage of participants
Percentage of Participants by Best Overall Response as Assessed by the Investigator Using RECIST v1.1
Percentage of participantsPertuzumab + Trastuzumab + Taxane
Complete Response (Confirmed)14.6
Partial Response (Confirmed)64.9
Stable Disease15.3
Progressive Disease4.2
Not Evaluable1.1
SecondarySubgroup Analysis by Age (≤65 vs. >65 Years): Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.1

The overall response rate was defined as the percentage of participants with complete response (CR) or partial response (PR) as their best confirmed response (≥4 weeks later), as assessed by the investigator using RECIST v1.1 from the start of study treatment until disease progression/recurrence or death. Responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants without post-baseline tumor assessments were considered non-responders.

Time frame:
Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression or death. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Number · Percentage of participants
Subgroup Analysis by Age (≤65 vs. >65 Years): Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.1
Percentage of participantsAge ≤65 YearsAge >65 Years
Subgroup Analysis by Age (≤65 vs. >65 Years): Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.181.7 (79.13 to 84.10)70.0 (63.63 to 75.85)
SecondarySubgroup Analysis by Taxane Chemotherapy: Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.1

The overall response rate was defined as the percentage of participants with complete response (CR) or partial response (PR) as their best confirmed response (≥4 weeks later), as assessed by the investigator using RECIST v1.1 from the start of study treatment until disease progression/recurrence or death. Responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants without post-baseline tumor assessments were considered non-responders.

Time frame:
Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression or death. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Number · Percentage of participants
Subgroup Analysis by Taxane Chemotherapy: Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.1
Percentage of participantsDocetaxelPaclitaxelNab-Paclitaxel
Subgroup Analysis by Taxane Chemotherapy: Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.178.4 (75.04 to 81.48)82.1 (78.40 to 85.44)77.4 (63.79 to 87.72)
SecondaryClinical Benefit Rate (CR or PR, or SD for at Least 6 Months) Based on Best Overall Response as Assessed by the Investigator Using RECIST v.1.1

The clinical benefit rate was defined as the percentage of participants whose best confirmed response (≥4 weeks later) was a complete response (CR) or partial response (PR), or stable disease (SD) that lasted at least 6 months, as assessed by the investigator using RECIST v1.1 from the start of study treatment until disease progression/recurrence or death. Clinical benefit responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.; SD = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least 20% increase in sum of diameters of target lesions and absolute increase of ≥5 mm), taking as reference the smallest sum diameters while on study.

Time frame:
Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Number · Percentage of participants
Clinical Benefit Rate (CR or PR, or SD for at Least 6 Months) Based on Best Overall Response as Assessed by the Investigator Using RECIST v.1.1
Percentage of participantsPertuzumab + Trastuzumab + Taxane
Clinical Benefit Rate (CR or PR, or SD for at Least 6 Months) Based on Best Overall Response as Assessed by the Investigator Using RECIST v.1.186.2 (84.14 to 88.13)
SecondaryDuration of Response as Assessed by the Investigator Using RECIST v1.1

Duration of response (DOR) was defined as the time from when a confirmed best overall response of complete response (CR) or partial response (PR) was first documented to first documented disease progression or death from any cause (whichever occurred first). DOR was analyzed using a Kaplan-Meier approach. Participants who had not progressed or died after having had a confirmed response were censored at the date of their last tumor measurement. Response was assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter until event occurrence or end of study. Responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From date of first confirmed response (CR or PR) to first documented disease progression or death from any cause, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Median · Months
Duration of Response as Assessed by the Investigator Using RECIST v1.1
MonthsPertuzumab + Trastuzumab + Taxane
Duration of Response as Assessed by the Investigator Using RECIST v1.120.01 (18.20 to 22.21)
SecondaryTime to Response for Participants With Best Overall Response of Complete Response or Partial Response, as Assessed by the Investigator Using RECIST v1.1

Time to response (TTR) was defined as the time from the first study treatment administration to the date of first confirmed response (CR or PR). TTR was analyzed using a Kaplan-Meier approach. Participants who did not have CR or PR were censored at the date of their last evaluable tumor assessment. Participants for whom no post-baseline tumor assessments were available were censored at Day 1. Responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From date of first study treatment until date of first confirmed response (CR or PR). The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Reported as:
Median · Months
Time to Response for Participants With Best Overall Response of Complete Response or Partial Response, as Assessed by the Investigator Using RECIST v1.1
MonthsPertuzumab + Trastuzumab + Taxane
Time to Response for Participants With Best Overall Response of Complete Response or Partial Response, as Assessed by the Investigator Using RECIST v1.12.464 (2.398 to 2.497)
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B) Questionnaire Total Score Over the Course of the Study

The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. Participants were given a series of statements in each subscale and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B total score, ranging from 0 to 148, was the sum of the scores for each subscale, provided that at least 80% of the items had been answered; a higher score indicated a better quality of life. If any of the 5 subscale scores were missing, the total score was also set to missing. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.

Time frame:
Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Mean · Score on a scale
Change From Baseline in Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B) Questionnaire Total Score Over the Course of the Study
Score on a scalePertuzumab + Trastuzumab + Taxane
Baseline (BL): Absolute Value at Visit99.87 ± 20.548
Change from BL at Cycle 30.40 ± 15.526
Change from BL at Cycle 6-1.93 ± 17.611
Change from BL at Cycle 90.87 ± 17.211
Change from BL at Cycle 123.03 ± 17.426
Change from BL at Cycle 153.33 ± 18.764
Change from BL at Cycle 183.80 ± 18.689
Change from BL at Cycle 214.06 ± 18.175
Change from BL at Cycle 243.59 ± 19.570
Change from BL at Cycle 273.14 ± 20.311
Change from BL at Cycle 303.75 ± 18.877
Change from BL at Cycle 333.58 ± 20.586
Change from BL at Cycle 363.16 ± 18.838
Change from BL at Cycle 391.66 ± 19.791
Change from BL at Cycle 422.08 ± 20.658
Change from BL at Cycle 452.22 ± 20.811
Change from BL at Cycle 481.51 ± 21.268
Change from BL at Cycle 511.95 ± 20.221
Change from BL at Cycle 540.52 ± 20.784
Change from BL at Cycle 570.54 ± 20.014
Change from BL at Cycle 600.20 ± 21.207
Change from BL at Cycle 630.61 ± 21.475
Change from BL at Cycle 660.44 ± 20.633
Change from BL at Cycle 69-0.75 ± 21.419
Change from BL at Cycle 72-1.16 ± 21.951
Change from BL at Cycle 75-1.14 ± 21.132
Change from BL at Cycle 780.11 ± 20.807
Change from BL at Cycle 81-1.03 ± 20.526
Change from BL at Cycle 84-1.67 ± 21.030
Change from BL at Cycle 870.62 ± 21.183
Change from BL at Cycle 900.00 ± 22.289
Change from BL at Cycle 930.99 ± 21.474
Change from BL at Cycle 962.36 ± 21.636
Change from BL at Cycle 991.36 ± 23.195
Change from BL at Cycle 1021.20 ± 21.262
Change from BL at Cycle 1053.13 ± 20.385
Change from BL at Cycle 1082.22 ± 23.617
Change from BL at Cycle 111-0.48 ± 22.585
Change from BL at Cycle 114-4.42 ± 22.323
Change from BL at Cycle 117-4.96 ± 16.232
Change from BL at Cycle 120-8.64 ± 13.187
Change from BL at Cycle 123-20.94 ± 2.357
Change from BL at End of Treatment-1.06 ± 19.923
Change from BL at Day 28 of Follow-Up-1.96 ± 21.201
SecondaryChange From Baseline in FACT-B Questionnaire Physical Well-Being Subscale Score Over the Course of the Study

The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. For the physical well-being subscale, participants were given a series of 7 statements and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B physical well-being subscale score, ranging from 0 to 28, was the sum of the scores for each statement only if at least 50% of items had been answered; the higher the score, the better the quality of life. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.

Time frame:
Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Mean · Score on a scale
Change From Baseline in FACT-B Questionnaire Physical Well-Being Subscale Score Over the Course of the Study
Score on a scalePertuzumab + Trastuzumab + Taxane
Baseline (BL): Absolute Value at Visit20.98 ± 6.044
Change from BL at Cycle 3-1.13 ± 5.557
Change from BL at Cycle 6-1.61 ± 5.994
Change from BL at Cycle 9-0.31 ± 5.604
Change from BL at Cycle 120.51 ± 5.599
Change from BL at Cycle 150.51 ± 5.652
Change from BL at Cycle 180.69 ± 5.543
Change from BL at Cycle 210.73 ± 5.616
Change from BL at Cycle 240.61 ± 5.690
Change from BL at Cycle 270.47 ± 5.761
Change from BL at Cycle 300.71 ± 5.584
Change from BL at Cycle 330.56 ± 5.894
Change from BL at Cycle 360.39 ± 5.512
Change from BL at Cycle 39-0.04 ± 5.647
Change from BL at Cycle 420.22 ± 5.604
Change from BL at Cycle 450.09 ± 5.698
Change from BL at Cycle 480.11 ± 5.564
Change from BL at Cycle 510.22 ± 5.280
Change from BL at Cycle 54-0.26 ± 5.765
Change from BL at Cycle 57-0.35 ± 5.695
Change from BL at Cycle 60-0.10 ± 5.630
Change from BL at Cycle 63-0.20 ± 5.696
Change from BL at Cycle 660.29 ± 5.338
Change from BL at Cycle 69-0.60 ± 5.579
Change from BL at Cycle 72-0.35 ± 5.494
Change from BL at Cycle 75-0.72 ± 5.507
Change from BL at Cycle 78-0.44 ± 5.379
Change from BL at Cycle 81-0.65 ± 5.029
Change from BL at Cycle 84-0.81 ± 5.249
Change from BL at Cycle 87-0.36 ± 5.391
Change from BL at Cycle 90-0.66 ± 5.332
Change from BL at Cycle 93-0.42 ± 5.788
Change from BL at Cycle 96-0.28 ± 5.178
Change from BL at Cycle 99-0.21 ± 5.474
Change from BL at Cycle 102-0.80 ± 5.269
Change from BL at Cycle 105-0.07 ± 5.133
Change from BL at Cycle 1080.07 ± 5.775
Change from BL at Cycle 1110.38 ± 5.309
Change from BL at Cycle 114-1.70 ± 4.950
Change from BL at Cycle 117-1.83 ± 3.474
Change from BL at Cycle 120-2.38 ± 3.092
Change from BL at Cycle 123-5.58 ± 2.946
Change from BL at End of Treatment-0.73 ± 6.366
Change from BL at Day 28 of Follow-Up-0.95 ± 6.393
SecondaryChange From Baseline in FACT-B Questionnaire Social Well-Being Subscale Score Over the Course of the Study

The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. For the social well-being subscale, participants were given a series of 7 statements and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B social well-being subscale score, ranging from 0 to 28, was the sum of the scores for each statement only if at least 50% of items had been answered; the higher the score, the better the quality of life. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.

Time frame:
Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Mean · Score on a scale
Change From Baseline in FACT-B Questionnaire Social Well-Being Subscale Score Over the Course of the Study
Score on a scalePertuzumab + Trastuzumab + Taxane
Baseline (BL): Absolute Value at Visit22.24 ± 4.993
Change from BL at Cycle 3-0.41 ± 4.145
Change from BL at Cycle 6-1.09 ± 4.320
Change from BL at Cycle 9-1.02 ± 4.728
Change from BL at Cycle 12-1.19 ± 4.846
Change from BL at Cycle 15-1.28 ± 4.949
Change from BL at Cycle 18-1.19 ± 4.986
Change from BL at Cycle 21-1.24 ± 4.881
Change from BL at Cycle 24-1.26 ± 4.856
Change from BL at Cycle 27-1.48 ± 4.994
Change from BL at Cycle 30-1.18 ± 5.107
Change from BL at Cycle 33-1.45 ± 4.852
Change from BL at Cycle 36-1.54 ± 4.953
Change from BL at Cycle 39-1.77 ± 5.066
Change from BL at Cycle 42-1.73 ± 5.154
Change from BL at Cycle 45-1.50 ± 5.238
Change from BL at Cycle 48-1.84 ± 5.475
Change from BL at Cycle 51-2.01 ± 5.657
Change from BL at Cycle 54-1.77 ± 5.236
Change from BL at Cycle 57-1.88 ± 5.117
Change from BL at Cycle 60-2.01 ± 5.528
Change from BL at Cycle 63-2.18 ± 5.278
Change from BL at Cycle 66-2.19 ± 5.586
Change from BL at Cycle 69-2.24 ± 5.434
Change from BL at Cycle 72-2.49 ± 5.846
Change from BL at Cycle 75-2.40 ± 5.777
Change from BL at Cycle 78-2.33 ± 5.676
Change from BL at Cycle 81-2.53 ± 5.609
Change from BL at Cycle 84-2.96 ± 5.624
Change from BL at Cycle 87-2.29 ± 5.487
Change from BL at Cycle 90-2.38 ± 5.355
Change from BL at Cycle 93-1.97 ± 5.102
Change from BL at Cycle 96-1.94 ± 4.831
Change from BL at Cycle 99-2.07 ± 5.316
Change from BL at Cycle 102-1.70 ± 4.258
Change from BL at Cycle 105-1.76 ± 4.074
Change from BL at Cycle 108-1.75 ± 3.387
Change from BL at Cycle 111-1.94 ± 3.663
Change from BL at Cycle 114-2.31 ± 3.386
Change from BL at Cycle 117-1.83 ± 3.600
Change from BL at Cycle 120-2.85 ± 5.485
Change from BL at Cycle 123-1.92 ± 2.946
Change from BL at End of Treatment-1.29 ± 4.911
Change from BL at Day 28 of Follow-Up-1.61 ± 5.080
SecondaryChange From Baseline in FACT-B Questionnaire Emotional Well-Being Subscale Score Over the Course of the Study

The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. For the emotional well-being subscale, participants were given a series of 6 statements and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B emotional well-being subscale score, ranging from 0 to 24, was the sum of the scores for each statement only if at least 50% of items had been answered; the higher the score, the better the quality of life. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.

Time frame:
Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Mean · Score on a scale
Change From Baseline in FACT-B Questionnaire Emotional Well-Being Subscale Score Over the Course of the Study
Score on a scalePertuzumab + Trastuzumab + Taxane
Baseline (BL): Absolute Value at Visit15.08 ± 4.990
Change from BL at Cycle 31.69 ± 4.219
Change from BL at Cycle 61.53 ± 4.526
Change from BL at Cycle 91.64 ± 4.624
Change from BL at Cycle 122.02 ± 4.686
Change from BL at Cycle 151.98 ± 4.778
Change from BL at Cycle 182.03 ± 4.861
Change from BL at Cycle 212.17 ± 4.877
Change from BL at Cycle 242.19 ± 5.040
Change from BL at Cycle 272.21 ± 5.171
Change from BL at Cycle 302.17 ± 4.763
Change from BL at Cycle 332.21 ± 5.275
Change from BL at Cycle 362.32 ± 5.130
Change from BL at Cycle 391.99 ± 5.115
Change from BL at Cycle 421.96 ± 5.451
Change from BL at Cycle 452.25 ± 5.367
Change from BL at Cycle 481.82 ± 5.414
Change from BL at Cycle 512.32 ± 5.311
Change from BL at Cycle 541.84 ± 5.325
Change from BL at Cycle 571.80 ± 5.256
Change from BL at Cycle 601.59 ± 5.462
Change from BL at Cycle 631.70 ± 5.336
Change from BL at Cycle 661.52 ± 5.074
Change from BL at Cycle 691.83 ± 5.351
Change from BL at Cycle 721.56 ± 5.421
Change from BL at Cycle 751.58 ± 5.308
Change from BL at Cycle 781.72 ± 5.463
Change from BL at Cycle 812.01 ± 5.750
Change from BL at Cycle 842.06 ± 5.384
Change from BL at Cycle 871.97 ± 5.558
Change from BL at Cycle 902.08 ± 5.686
Change from BL at Cycle 932.17 ± 5.388
Change from BL at Cycle 962.40 ± 5.769
Change from BL at Cycle 992.30 ± 6.041
Change from BL at Cycle 1022.07 ± 5.949
Change from BL at Cycle 1052.58 ± 5.902
Change from BL at Cycle 1082.34 ± 6.721
Change from BL at Cycle 1111.19 ± 7.241
Change from BL at Cycle 1141.55 ± 7.944
Change from BL at Cycle 1171.33 ± 4.185
Change from BL at Cycle 1200.75 ± 2.217
Change from BL at Cycle 123-0.50 ± 2.121
Change from BL at End of Treatment0.30 ± 5.001
Change from BL at Day 28 of Follow-Up0.37 ± 5.193
SecondaryChange From Baseline in FACT-B Questionnaire Functional Well-Being Subscale Score Over the Course of the Study

The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. For the functional well-being subscale, participants were given a series of 7 statements and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B functional well-being subscale score, ranging from 0 to 28, was the sum of the scores for each statement only if at least 50% of items had been answered; the higher the score, the better the quality of life. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.

Time frame:
Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Mean · Score on a scale
Change From Baseline in FACT-B Questionnaire Functional Well-Being Subscale Score Over the Course of the Study
Score on a scalePertuzumab + Trastuzumab + Taxane
Baseline (BL): Absolute Value at Visit16.65 ± 6.096
Change from BL at Cycle 3-0.47 ± 4.961
Change from BL at Cycle 6-0.79 ± 5.437
Change from BL at Cycle 9-0.11 ± 5.572
Change from BL at Cycle 120.46 ± 5.577
Change from BL at Cycle 150.78 ± 5.758
Change from BL at Cycle 180.83 ± 5.797
Change from BL at Cycle 210.89 ± 5.804
Change from BL at Cycle 240.53 ± 5.903
Change from BL at Cycle 270.71 ± 6.064
Change from BL at Cycle 300.60 ± 5.961
Change from BL at Cycle 330.67 ± 6.209
Change from BL at Cycle 360.52 ± 5.687
Change from BL at Cycle 390.26 ± 5.927
Change from BL at Cycle 420.31 ± 6.038
Change from BL at Cycle 450.34 ± 6.049
Change from BL at Cycle 480.28 ± 6.227
Change from BL at Cycle 510.23 ± 5.931
Change from BL at Cycle 54-0.06 ± 6.090
Change from BL at Cycle 570.21 ± 5.925
Change from BL at Cycle 600.01 ± 6.100
Change from BL at Cycle 63-0.06 ± 6.178
Change from BL at Cycle 66-0.07 ± 6.264
Change from BL at Cycle 69-0.47 ± 6.476
Change from BL at Cycle 72-0.50 ± 6.378
Change from BL at Cycle 75-0.40 ± 6.391
Change from BL at Cycle 78-0.18 ± 6.197
Change from BL at Cycle 81-0.29 ± 6.046
Change from BL at Cycle 84-0.48 ± 6.022
Change from BL at Cycle 87-0.08 ± 6.250
Change from BL at Cycle 900.16 ± 6.587
Change from BL at Cycle 930.58 ± 6.161
Change from BL at Cycle 961.27 ± 6.663
Change from BL at Cycle 990.46 ± 6.651
Change from BL at Cycle 1020.96 ± 6.327
Change from BL at Cycle 1051.14 ± 5.922
Change from BL at Cycle 1081.42 ± 6.902
Change from BL at Cycle 1110.32 ± 6.507
Change from BL at Cycle 114-0.25 ± 6.439
Change from BL at Cycle 117-0.58 ± 5.316
Change from BL at Cycle 120-2.00 ± 3.916
Change from BL at Cycle 123-5.00 ± 2.828
Change from BL at End of Treatment-0.50 ± 6.132
Change from BL at Day 28 of Follow-Up-0.70 ± 6.558
SecondaryChange From Baseline in FACT-B Questionnaire Breast Cancer Subscale Score Over the Course of the Study

The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. For the breast cancer subscale, participants were given a series of 10 statements and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B breast cancer subscale score, ranging from 0 to 40, was the sum of the scores for each statement only if at least 50% of items had been answered; the higher the score, the better the quality of life. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.

Time frame:
Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Reported as:
Mean · Score on a scale
Change From Baseline in FACT-B Questionnaire Breast Cancer Subscale Score Over the Course of the Study
Score on a scalePertuzumab + Trastuzumab + Taxane
Baseline (BL): Absolute Value at Visit24.98 ± 6.296
Change from BL at Cycle 30.48 ± 5.101
Change from BL at Cycle 6-0.11 ± 5.759
Change from BL at Cycle 90.52 ± 5.633
Change from BL at Cycle 120.89 ± 5.770
Change from BL at Cycle 151.16 ± 6.180
Change from BL at Cycle 181.30 ± 6.043
Change from BL at Cycle 211.30 ± 5.898
Change from BL at Cycle 241.39 ± 6.231
Change from BL at Cycle 271.17 ± 6.043
Change from BL at Cycle 301.34 ± 5.968
Change from BL at Cycle 331.34 ± 6.113
Change from BL at Cycle 361.33 ± 6.030
Change from BL at Cycle 391.12 ± 6.210
Change from BL at Cycle 421.11 ± 6.499
Change from BL at Cycle 451.13 ± 6.414
Change from BL at Cycle 481.00 ± 6.679
Change from BL at Cycle 510.99 ± 6.430
Change from BL at Cycle 540.76 ± 6.555
Change from BL at Cycle 570.70 ± 6.355
Change from BL at Cycle 600.80 ± 6.586
Change from BL at Cycle 631.32 ± 6.960
Change from BL at Cycle 660.74 ± 6.822
Change from BL at Cycle 690.54 ± 6.532
Change from BL at Cycle 720.50 ± 7.142
Change from BL at Cycle 750.85 ± 6.925
Change from BL at Cycle 781.22 ± 6.899
Change from BL at Cycle 810.27 ± 7.100
Change from BL at Cycle 840.55 ± 6.690
Change from BL at Cycle 871.17 ± 6.882
Change from BL at Cycle 900.51 ± 7.313
Change from BL at Cycle 930.30 ± 7.163
Change from BL at Cycle 960.65 ± 6.240
Change from BL at Cycle 991.19 ± 6.957
Change from BL at Cycle 1020.56 ± 6.189
Change from BL at Cycle 1050.68 ± 6.399
Change from BL at Cycle 1080.19 ± 6.982
Change from BL at Cycle 1110.01 ± 6.814
Change from BL at Cycle 114-1.67 ± 5.963
Change from BL at Cycle 117-1.56 ± 5.842
Change from BL at Cycle 120-2.17 ± 6.055
Change from BL at Cycle 123-7.94 ± 7.307
Change from BL at End of Treatment0.88 ± 6.574
Change from BL at Day 28 of Follow-Up0.66 ± 6.477

Adverse events

Collected over From Baseline until 28 days after last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pertuzumab + Trastuzumab + Taxane658/1,436 (45.8%)535/1,436 (37.3%)1,394/1,436 (97.1%)
Most frequent serious events
Showing 10 of 301
Most frequent serious events
EventPertuzumab + Trastuzumab + Taxane
Febrile neutropeniaBlood and lymphatic system disorders71/1436
NeutropeniaBlood and lymphatic system disorders47/1436
DiarrhoeaGastrointestinal disorders36/1436
PneumoniaInfections and infestations26/1436
Drug hypersensitivityImmune system disorders20/1436
PyrexiaGeneral disorders18/1436
Ejection fraction decreasedInvestigations18/1436
DyspnoeaRespiratory, thoracic and mediastinal disorders16/1436
CellulitisInfections and infestations15/1436
Urinary tract infectionInfections and infestations15/1436
Most frequent other events
Showing 10 of 66
Most frequent other events
EventPertuzumab + Trastuzumab + Taxane
DiarrhoeaGastrointestinal disorders974/1436
AlopeciaSkin and subcutaneous tissue disorders693/1436
NauseaGastrointestinal disorders512/1436
FatigueGeneral disorders457/1436
AstheniaGeneral disorders426/1436
RashSkin and subcutaneous tissue disorders365/1436
VomitingGastrointestinal disorders340/1436
HeadacheNervous system disorders328/1436
Neuropathy peripheralNervous system disorders328/1436
ArthralgiaMusculoskeletal and connective tissue disorders328/1436

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pertuzumab + Trastuzumab + Taxane
Mean54.4 ± 12.10
Sex: Female, Male
Sex: Female, Male(Participants)Pertuzumab + Trastuzumab + Taxane
Female1429
Male7
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pertuzumab + Trastuzumab + Taxane
Caucasian1032
Black9
Asian88
Native American28
Other57
Not Applicable as per Local Regulations222
Age Categorical (≤65 or >65 Years Old)
Age Categorical (≤65 or >65 Years Old)(Participants)Pertuzumab + Trastuzumab + Taxane
≤65 Years Old1167
>65 Years Old269
Ethnicity
Ethnicity(Participants)Pertuzumab + Trastuzumab + Taxane
Hispanic/Latino269
Chinese57
Japanese2
Mixed Ethnicity18
Indian21
Other495
Not Applicable as per Local Regulations574
Geographic Region of Enrollment
Geographic Region of Enrollment(Participants)Pertuzumab + Trastuzumab + Taxane
Europe1009
Asia177
North America34
South America121
Africa71
Other (Australia)24
Eastern Cooperative Oncology Group (ECOG) Performance Status at Baseline
Eastern Cooperative Oncology Group (ECOG) Performance Status at Baseline(Participants)Pertuzumab + Trastuzumab + Taxane
Grade 0 or 11371
Grade 263
Missing2
Visceral Disease at Baseline
Visceral Disease at Baseline(Participants)Pertuzumab + Trastuzumab + Taxane
Visceral Disease992
Non-visceral Disease444

5 further baseline measures are reported on the registry.

08

Study locations

299 sites
  • CPMC; Service d'Oncologie Médicale
    Algiers, 16000, Algeria
  • Centro Oncologico Riojano Integral (CORI)
    La Rioja, F5300COE, Argentina
  • Instituto de Oncología de Rosario
    Rosario, S2000KZE, Argentina
  • Canberra Hospital; Medical Oncology
    Canberra, Australian Capital Territory 2606, Australia
  • Royal Prince Alfred Hospital; Medical Oncology
    Camperdown, New South Wales 2050, Australia
  • HOCA Chermside
    Chermside, Queensland 4032, Australia
  • Mater Hospital; Cancer Services
    South Brisbane, Queensland 4101, Australia
  • Austin and Repatriation Medical Centre; Cancer Services
    Melbourne, Victoria 3084, Australia
  • Royal Melbourne Hospital; Hematology and Medical Oncology
    Parkville, Victoria 3052, Australia
  • Lkh-Univ. Klinikum Graz; Klinik Für Gynäkologie
    Graz, 8036, Austria
  • LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie
    Graz, 8036, Austria
  • Tiroler Landeskrankenanstalten Ges.M.B.H.; Abt. Für Gynäkologie
    Innsbruck, 6020, Austria
  • Ordensklinikum Linz Barmherzige Schwestern; Abt. fur Innere Medizin 1
    Linz, 4010, Austria
  • Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.
    Salzburg, 5020, Austria
  • A.Ö. Lhk; Ii. Medizinische Abt. Mit Schwerpunkt Gaströnter. & Onkologie
    Steyr, 4400, Austria
  • Medizinische Universität Wien; Univ.Klinik für Frauenheilkunde - Klinik für Gynäkologie
    Wien, 1090, Austria
  • Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie
    Wien, 1090, Austria
  • UZ Brussel
    Brussel, 1090, Belgium
  • UZ Antwerpen
    Edegem, 2650, Belgium
  • UZ Gent
    Gent, 9000, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • CHU Sart-Tilman
    Liège, 4000, Belgium
  • Oncologistas Associados
    Rio de Janeiro, RJ 22271-110, Brazil
  • Hospital Sao Lucas - PUCRS
    Porto Alegre, RS 90610-000, Brazil
  • Hospital Amaral Carvalho
    Jau, SP 17210-120, Brazil
  • Hospital Sirio Libanes; Centro de Oncologia
    Sao Paulo, SP 01308-050, Brazil
  • Hospital Perola Byington
    Sao Paulo, SP 01317-000, Brazil
  • Hospital das Clinicas - FMUSP
    Sao Paulo, SP 05403-000, Brazil
  • Hospital Sao Jose
    São Paulo, SP CEP 01321-001, Brazil
  • Cross Cancer Institute ; Dept of Medical Oncology
    Edmonton, Alberta T6G 1Z2, Canada
  • Lions Gate Hospital
    North Vancouver, British Columbia V7L 2L7, Canada
  • Bcca - Vancouver Island Cancer Centre; Oncology
    Victoria, British Columbia V8R 6V5, Canada
  • Queen Elizabeth II Health Sciences Centre; Oncology
    Halifax, Nova Scotia B3H 2Y9, Canada
  • William Osler Health System Brampton Civic Hospital
    Brampton, Ontario L6R 3J7, Canada
  • Grand River Hospital
    Kitchener, Ontario N2G 1G3, Canada
  • Sunnybrook Odette Cancer Centre
    Toronto, Ontario M4N 3M5, Canada
  • CSSS champlain - Charles-Le Moyne
    Greenfield Park, Quebec J4V 2H1, Canada
  • Centre Hospitalier de l'Université de Montréal (CHUM)
    Montreal, Quebec H2X 0C2, Canada
  • McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology
    Montreal, Quebec H3T 1E2, Canada
  • Beijing Cancer Hospital
    Beijing, 100142, China
  • Southwest Hospital , Third Military Medical University
    Chongqing, 400038, China
  • Sun Yet-sen University Cancer Center
    Guangzhou, 510060, China
  • Heilongjiang Provincial Tumor Hospital
    Harbin, 150040, China
  • Jiangsu Cancer Hospital
    Nanjing, 210009, China
  • Fudan University Shanghai Cancer Center
    Shanghai, 200120, China
  • Tianjin Cancer Hospital
    Tianjin, 300060, China
  • The First Affiliated Hospital of The Fourth Military Medical University (Xijing Hospital)
    Xi'an, 710032, China
  • First Affiliated Hospital of Medical College of Xi'an Jiaotong University
    Xi'an, 710061, China
  • Hospital Solca Portoviejo; Oncologia
    Portoviejo, EC130104, Ecuador
  • Hospital Solca Quito; Oncologia
    Quito, EC170124, Ecuador
  • Manial Specialized Hospital; Oncology
    Cairo, 11555, Egypt
  • El Mokatam HIO Hospital
    Cairo, 11654, Egypt
  • Nci; Oncology Dept
    Cairo, 11796, Egypt
  • North Estonia Medical Centre Foundation; Oncology Center
    Tallinn, 13419, Estonia
  • Tartu University Hospital; Clinic of Hematology and Oncology
    Tartu, 50406, Estonia
  • Helsinki University Central Hospital; Oncology Clinics
    Helsinki, 00029, Finland
  • Satakunta Central Hospital; Oncology
    Pori, 28500, Finland
  • Tampere University Hospital; Dept of Oncology
    Tampere, 33520, Finland
  • Turku Uni Central Hospital; Oncology Clinics
    Turku, 20520, Finland
  • Clinique De L Europe; Radiotherapie Chimiotherapie
    Amiens, 80090, France
  • ICO Paul Papin; Oncologie Medicale.
    Angers, 49055, France
  • Polyclinique Bordeaux Nord Aquitaine; Chimiotherapie Radiotherapie
    Bordeaux, 33077, France
  • Centre Hospitalier Fleyriat; Oncologie/Hematologie
    Bourg En Bresse, 01012, France
  • Centre Leonard De Vinci;Chimiotherapie
    Dechy, 59187, France
  • Fondation Clement Drevon; Oncology
    Dijon, 21000, France
  • Centre Georges Francois Leclerc; Oncologie 3
    Dijon, 21079, France
  • Clinique Sainte Marguerite; Oncologie Medicale
    Hyeres, 83400, France
  • Polyclinique de Blois; Chimiotherapie Ambulatoire
    La Chaussee St Victor, 41260, France
  • Clinique Victor Hugo
    LeMans, 72000, France
  • Polyclinique Du Bois; Centre Bourgogne
    Lille, 59000, France
  • Clinique Chenieux; Oncology
    Limoges, 87039, France
  • Centre Leon Berard; Departement Oncologie Medicale
    Lyon, 69373, France
  • Institut Paoli Calmettes; Oncologie Medicale
    Marseille, 13273, France
  • Centre Azureen De Cancerologie; Cons externes
    Mougins, 06250, France
  • Hopital Cochin; Unite Fonctionnelle D Oncologie
    Paris, 75014, France
  • Hopital Hotel Dieu; Oncologie Medicale
    Paris, 75181, France
  • Institut Curie; Oncologie Medicale
    Paris, 75231, France
  • Hopital Saint Louis; Service Onco Thoracique
    Paris, 75475, France
  • Centre Catalan D' Oncologie
    Perpignan, 66000, France
  • Polyclinique De Courlancy; Centre Radiotherapie Oncologie
    Reims, 51057, France
  • Centre Eugene Marquis; Unite Huguenin
    Rennes, 35042, France
  • Centre Rene Huguenin; ONCOLOGIE GENETIQUE
    Saint Cloud, 92210, France
  • Chp Saint Gregoire; Cancerologie Radiotherapie
    Saint Gregoire, 35768, France
  • Ico Rene Gauducheau; Oncologie
    Saint Herblain, 44805, France
  • Institut D Oncologie Medical
    Strasbourg, 67000, France
  • Institut Claudius Regaud; Departement Oncologie Medicale
    Toulouse, 31059, France
  • Hopital Prive Drome Ardeche; Hopital De Jour
    Valence, 26000, France
  • Clinique Onco Des Dentellieres; Chimiotherapie Radiotherapie
    Valenciennes, 59300, France
  • Klinikum am Bruderwald; Frauenklinik
    Bamberg, 96049, Germany
  • Gynaekologicum Bremen; Prof. Dr. Willibald Schröder
    Bremen, 28211, Germany
  • Universitätsklinikum Erlangen; Frauenklinik
    Erlangen, 91054, Germany
  • Universitätsklinikum Essen; Zentrum Für Frauenheilkunde
    Essen, 45122, Germany
  • Klinikum Esslingen; Klinik für Frauenheilkunde und Geburtshilfe
    Esslingen, 73730, Germany
  • AGAPLESION Markus-Krankenhaus
    Frankfurt, 60431, Germany
  • SRH Wald-Klinikum Gera; Klinik für Frauenheilkunde und Geburtshilfe
    Gera, 07548, Germany
  • Universitätsklinikum Hamburg-Eppendorf; Frauenklinik
    Hamburg, 20246, Germany
  • Gynaekologisch-Onkologische Schwerpunktpraxis Prof. Dr. med. Lueck, Dr. Schrader und Dr. Noeding
    Hannover, 30177, Germany
  • Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Universitätsklinikum des Saarlandes; Klinik f. Frauenheilkunden und Geburtshilfe
    Homburg/Saar, 66424, Germany
  • St.-Vincenz-Krankenhaus; Frauenklinik
    Limburg, 65549, Germany

Showing the first 100 of 299 sites across 39 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D; PERUSE investigators. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann Oncol. 2019 May 1;30(5):766-773. doi: 10.1093/annonc/mdz061. PubMed 30796821 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2012 to primary completion in Sep 2019, 87 months.

Results were first posted in Sep 2020, 1 year after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 87 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2012
First posted
Apr 5, 2012
StartActual
Jun 1, 2012
Primary completionActual
Sep 20, 2019
CompletionActual
Sep 20, 2019
Results first posted
Sep 25, 2020
Last update
Sep 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01572038
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 5, 2012
Start date
Jun 1, 2012
Primary completion
Sep 20, 2019
Completion
Sep 20, 2019
Results posted
Sep 25, 2020
Last update
Sep 25, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pertuzumab

Start the discussion